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ABSTRACT
The p53 tumor suppressor is a sequence-specific DNA binding protein that activates gene
transcription to regulate cell survival and proliferation. The activation process involves posttranslational modifications that suppress p53 degradation by MDM2 and increase p53 DNA binding
affinity. p53 is mutated in ~50% of human tumors, with higher frequency in specific tumor types and
after relapse. Mutated p53 loses transcriptional activity and gains new functions that drive tumor
progression. Both N-terminus (NT) and C-terminus (CT) of p53 contain intrinsically disordered
regions. The p53 CT has well-documented effects in regulating DNA binding. CT truncated p53
mutants showed defective DNA binding and transcriptional activities. However, the effects of NT on
p53 DNA binding and its underlying mechanisms are elusive. Hence, this study is to elucidate the role
of the p53 NT as an intrinsically disordered region in p53 regulation.
The goal of the first part of this study was to investigate the effects of NT on p53 DNA binding
and its molecular mechanisms. We showed that transactivation domain 2 (TAD2) and proline-rich
region (PRR) inhibit DNA binding by directly interacting with the sequence-specific DNA binding
domain (DBD). NMR spectroscopy revealed that TAD2 and PRR interact with the DBD at or near the
DNA binding surface, possibly acting as a nucleic acid mimetic to competitively block DNA binding.
In vitro and in vivo DNA binding analyses showed that the NT reduced p53 DNA binding affinity but
improved the ability of p53 to distinguish between specific and nonspecific sequences.
The second part of this study was to explore the regulation and significance of the NT-DBD
interaction in both wild-type and mutant p53. MDMX inhibits p53 binding to specific target
promoters but stimulates binding to nonspecific chromatin sites. The phosphomimetic mutations of
T55 alter the intramolecular interactions in p53. Furthermore, T55 phosphorylation is induced by
vi

DNA damaging compounds and T55A mutant p53 manifests defective growth suppression activities.
The results suggest that p53 NT regulates the affinity and specificity of DNA binding by the DBD. p53
NT-interacting proteins and post-translational modifications may regulate DNA binding partly by
modulating the NT-DBD interaction in p53. Also, we demonstrated stronger NT-DBD interaction in
mutant p53, especially the conformational mutations.
Overall, our results established a novel form of p53 regulation via the NT-DBD interaction in
p53, highlighting the importance of N terminus in p53 DNA binding and function.
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CHAPTER 1 BACKGROUND
1.1 p53 structure and function
1.1.1 p53 history
In 1979, most of the researchers focused on oncogenes encoded by cancer-causing viruses. A
non-viral protein with a molecular mass of 53 kDa was discovered during the immunoprecipitation
of SV40 large T-antigen from the serum of animals bearing SV40-induced tumors1. p53 was thought
to be the cellular oncoprotein that mediates the transforming function of this tumor virus1. Later,
missense mutant p53 cDNA was mistakenly cloned and found to transform cells in cooperation with
oncogenic proteins, which suggested the role of p53 as an oncogene2. In 1989, Levine et al. proposed
p53 as a tumor suppressor after observing the inhibition of transformation by wild-type (wt) p533.
Subsequent identification of p53 mutation and loss of heterozygosity in colon cancer confirmed p53’s
role as a tumor suppressor. In the following decades, cell-cycle arrest and cell death were identified
to be critical cellular consequences of p53 induction in response to DNA damage4. As a transcription
factor, p53 functions via binding to specific sequences and transactivating target gene expressions.
1.1.2 p53 structure
p53 is encoded by the TP53 gene. TP53 locates on the short arm of chromosome 17 (17p13.1)
with 11 exons coding a peptide of 393 amino acids. As shown in Figure 1, p53 is a multi-domain
protein composed of two consecutive N-terminal (NT) transactivation domains (TAD1 and TAD2), a
proline-rich region (PRR), a DNA-binding domain (DBD), a nuclear localization signal (NLS), an
oligomerization domain (OD), and a C-terminal regulatory domain (CT). The intrinsically disordered
TAD domains are responsible for providing binding sites for other proteins such as transcription
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coregulators and kinases. They also interact with MDM2 and MDMX to mediate negative regulations
on p53. Multiple kinases regulate p53 activation via phosphorylation of serine and threonine in NT.
The PRR with five copies of the sequence PXXP is necessary for p53-induced cell cycle arrest and cell
death. The 200 amino acids in the DBD domain fold into two β-sheets packed as a β-sandwich. Four
positively charged DBDs in a p53 tetramer cooperatively bind to DNA response elements in a
sequence-specific manner. The OD accounts for the formation of tetramers of p53; it also mediates
the dominant-negative effects of mutant p53 by forming heterodimers. CT binds to DNA
nonspecifically, and an intact CT enables p53 binding to DNA in a sequence-dependent manner via
the modulation of DBD conformations. Multiple post-translational modifications of lysine and
arginine residues in CT regulate p53 DNA binding strength and specificity5.

Figure 1 The domain structure of the human p53 protein.
From the N-terminus to C-terminus: transactivation domain 1 (TAD1); transactivation domain 2 (TAD2);
proline-rich region (PRR); DNA-binding domain (DBD); nuclear localization signal (NLS); oligomerization
domain (OD); and C-terminal regulatory domain (CT).

1.1.3 Canonical functions of p53
As a tumor suppressor, p53 engages in a variety of antiproliferative programs that limit
tumorigenesis, including cell cycle arrest, apoptosis, and senescence. p53 is kept at a relatively low
level in physiological conditions. DNA damage, oncogene activation, or hypoxia activate p53 through
several steps. First, post-translational modifications of p53 NT disrupt p53 interaction with MDM2,
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the major negative regulator that inhibits and degrades p53. Second, CBP/p300-mediated acetylation
of p53 CT activates p53 DNA-binding abilities. Fully activated p53 binds to specific promoters to
regulate transcription of its target genes with the assistance of cofactors. These target genes
cooperatively mediate tumor suppression via the regulation of different cellular activities, such as
cell cycle arrest, apoptosis, senescence, and metabolism.
In normal cells, cell division is tightly controlled by a series of molecular and biochemical
signalling pathways. The process of cell division can be divided into four phases, including G1, S, G2,
and M phases. To enter the S phase for DNA replication, cells need to pass the G1/S checkpoint to
ensure DNA integrity. Upon DNA damage, p53 is activated via DNA-damage-response, initiating the
transcription of p21, which binds to and inhibits cyclin-CDK complexes to prevent the S phase entry6.
GADD45 and 14-3-3σ are also essential p53 target genes that contribute to cell cycle arrest via
binding to and sequestering CDC2 in the cytoplasm, preventing M phase entry7-9. Thus, p53 is
important for the proper function of G1/S and G2/M checkpoints that maintains genomic stability.
Apoptosis is programmed cell death with characteristic morphology changes, including cell
shrinkage, nuclear fragmentation, chromatin condensation, chromosomal DNA fragmentation, and
global mRNA decay. Apoptosis can be mediated via two distinct but ultimately converging pathways:
the intrinsic and extrinsic pathways. The intrinsic pathway is initiated by cellular stresses, such as
DNA damage or ER stress, and mediated by actions of BCL-2 family proteins on the mitochondrial
outer membrane. Under stress, Bax, PUMA, and Noxa are transcribed by p5310-12. Bax and Bak are
freed from anti-apoptotic Bcl-2 family proteins and depolarize the mitochondrial outer membrane to
release cytochrome C, leading to the activation of Caspase 9 ultimately13. The extrinsic pathway
originates from the activation of tumor necrosis factor receptors on the cell surface by specific
ligands. Tumor necrosis factor receptor genes Fas and DR5 are direct targets of p53, sensitizing cells
to death receptor ligands14,15. p53 also induces apoptosis in a transcription-independent manner.
Monoubiquitinated p53 translocates to mitochondria and induces outer mitochondrial membrane
3

permeabilization by interacting with Bcl-2 family members directly16. In summary, p53 initiates
apoptosis via different mechanisms.
Senescence is a stress response in which cells withdraw from cell cycle and fail to proliferate
in response to growth factors or mitogens. Flat or enlarged cell shape and increased expression of
characteristic biomarkers, including staining for β-galactosidase at pH of 6.0, cyclin-dependent
kinase inhibitors and transcriptionally inactive heterochromatic structure, can be observed in cells
undergoing senescence. Senescence can be triggered by multiple mechanisms, including telomere
shortening, DNA double-strand breaks, and importantly, the intracellular accumulation of reactive
oxygen species (ROS) in mitochondria17. The activation of p53 to elicit p21-mediated cell cycle arrest
is a critical mediator of senescence. P21 is upregulated during senescence, allowing an irreversible
senescent arrest, and p21 deletion abrogates senescence in some cases18,19. Cellular senescence is
intimately related with aging; the accumulation of senescent cells limits tissue renewal, perturbs
normal tissue homeostasis, and ultimately elicits organismal aging. The observation of accelerated
aging in multiple groups of p53 knock-in (KI) mice suggests a negative role of p53 in aging, which
could be attributed to stem cell loss by PUMA induction20. However, KI mice with phosphorylationresistant alanine substitution of serine 18 in p53 also developed signs of accelerated aging, indicating
the protection of aging-related damage by physiological p53 activity21. Evidence from superARF/p53 mouse models supported the anti-aging effects of p53 by showing that p53 and ARF
transgenic mice manifested increased lifespan22. Thus, p53 regulates both senescence and aging in a
context-dependent manner.
Cellular metabolism refers to the chemical reactions that provide energy for cell growth,
reproduction, structure maintenance, and responses to environmental stresses. Wt p53 promotes
mitochondrial respiration over glycolysis through the transactivation of several key mediators in
metabolic pathways. p53 promotes the expression of synthesis of cytochrome c oxidase 2 (SCO2), a
central mediator of respiratory chain function, and suppresses glycolysis by directly transactivating
4

inhibitors of it, such as RRAD and TIGAR genes23-25. Additionally, p53 inhibits glucose consumption
by directly binding to and inactivating glucose-6-phosphate dehydrogenase, the first and ratelimiting enzyme of the pentose phosphate pathway26. p53 also plays a role in lipid metabolism. It
enhances fatty acid oxidation through transcriptional regulation of carnitine palmitoyltransferase 1C
(CPT1C), promoting the transport of activated fatty acids into the mitochondria27.
1.1.4 Non-canonical functions of p53
Recently, ferroptosis has emerged as a new form of iron-dependent cell death characterized
by the accumulation of lipid peroxides28. Metabolic dysfunctions initiate ferroptosis by elevating the
production of ROS independent of mitochondria. SLC7A11 is a critical mediator of ferroptosis and
protects tumor cells from ferroptosis by targeting iron metabolism and lipid peroxidation29. p53
inhibits cellular cysteine uptake and sensitizes cells to ferroptosis by suppressing the transcription
of SLC7A11. Intriguingly, the p533KR (K117/161/162) mutation abrogates the classical functions of
p53 but retains the regulation of SLC7A1129. However, an additional loss of K98 acetylation (p534KR)
eliminates the regulation of SLC7A11 by p5330. Nutlin activates p53 by inhibiting p53-MDM2
interactions. Different from Nutlin, which induces reversible cell-cycle arrest but not cell death in
most cancer cells, the combination of p53 activation and ferroptosis induction results in massive cell
death. It indicates p53-mediated ferroptosis is independent of other functions of p53, such as
apoptosis and cell cycle arrest. On the contrary, p53 appears to inhibit ferroptosis by transcriptionindependently sequestering of DPP4 in the nucleus in colorectal cancer cells31. p53-p21 axis delays
ferroptosis onset by enhancing glutathione levels and maintaining redox balance, which promotes
cancer cell survival32. Therefore, p53 can promote or inhibit ferroptosis in cell- and contextdependent manners. The induction of ferroptosis might elicit extra tumor suppression effects as a
byproduct of p53-activating compounds.
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Mevalonate pathway (MVA) is responsible for the de novo synthesis of cholesterol and
isoprenoids, intersecting with many important signalling pathways, such as Hippo, Hedgehog, and
immune responses33-35. Previous studies have established a feed-forward loop between mutant p53
and MVA activation that promotes oncogenesis36. MVA stabilizes mutant p53, and mutant p53
promotes the transcription of critical MVA enzymes36. Large scale population studies confirmed the
activation of MVA in cancer by showing that pharmaceutical inhibition of MVA correlates with lower
mortality of cancer patients37,38. Interestingly, recent findings demonstrate that wt p53 inhibits MVA
by blocking the activation of SREBP-2, a central transcriptional regulator of MVA39. Pharmaceutical
inhibition of MVA by HMG-CoA reductase inhibitors restricts the formation of hepatocellular
carcinomas in mice with p53 loss, corroborating the importance of MVA in wt p53-mediated tumor
suppression39. Thus, the inhibition of MVA might benefit cancer patients carrying either wt or mutant
p53 via distinct mechanisms. Yes-associated protein 1 (YAP) and transcriptional coactivator with
PDZ-binding motif (TAZ) are major effectors of the Hippo signalling pathway, regulating multiple
biological processes, such as cell-cell communication, cytoskeletal remodelling, metabolism, and
tumorigenesis40. MVA activates YAP/TAZ activity via promoting their nuclear accumulation33. The
inhibition of MVA by statin opposes YAP/TAZ nuclear localization and transcriptional responses.
Aside from the indirect regulation of YAP/TAZ through MVA inhibition, p53 suppresses YAP via other
mechanisms. First, the transactivation of Ptpn14 by p53 negatively regulates YAP41. Second,
transcription of Large tumor suppressor kinase 2 (LATS2) is promoted by p5342. LATS2 acts as
another critical regulator of YAP by sequestrating YAP in the cytoplasm for proteasome degradation43.
Interestingly, LATS2 also binds to and inhibits MDM2, leading to p53 activation during mitotic
stress42. The reciprocal crosstalk between p53 and YAP pathways highlights the importance of p53
in tumor suppression; further studies are warranted to unveil how these pathways cooperate to
maximize anti-tumor response.
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Growing evidence suggests the involvement of p53 in epigenetic regulation. Bromodomain
containing protein 7 (BRD7), an important component of the SWI/SNF chromatin remodelling
complex, was found to be required for efficient p53-mediated transcription of a subset of target genes.
BRD7 promotes histone acetylation at the promoter of p53 specific target genes, including p21 and
MDM2, and interacts with p300 to assist p53 acetylation44. The deletion of BRD7 locus was observed
in breast tumors with wt, but not mutant, p53. Besides, BRD4 interacts with wt p53, BRD4 inhibitor
JQ1 synergizes with Nutlin in killing acute myeloid leukemia cells45,46. Of note, the interaction
between BRD4 and p53 is not mediated by a bromodomain. p53 controls heterochromatin relaxation
by inducing the expression of demethylase JMJD2b and the suppression of SUV39H1 through p53p21-E2F axis47. Simultaneous regulation of JMJD2b and SUV39H1 by p53 inhibits H3K9 methylation
and thereby facilitates DNA damage repair after ionizing irradiation47. Furthermore, MDM2
suppresses p53 through the recruitment of SUV39H1 and EHMT1 methyltransferases to histone H3
at the promoter of p53 specific target genes, leading to the silence of p53 target genes48. Taken
together, the interaction of p53 with epigenetic regulators not only redefines p53 pathways but also
provides a novel strategy to harness the tumor-suppressive effects of p53.
p53 appears to inhibit gene expression. Early data suggested that p53 can directly repress
gene transcription via binding to p53 response elements or sequestration of transcriptional
machinery49. However, recent genomic studies opposed the conclusion by showing an exclusive
upregulation of “default” p53 target genes and no enrichments of p53 at the promoter of
downregulated genes50. The involvement of adaptors in p53-induced gene suppression is also
questioned since binding boxes of those adaptors were not enriched at loci bound by p5351. Thus,
direct inhibition of transcription might not be a viable explanation of p53-dependent transcriptional
repression. Considering that most p53-repressed genes are involved in cell cycle regulation, an
indirect p53-p21-DREAM pathway is proposed52. DREAM is composed of dimerization partner, RBlike, E2F, and multivulval class B (MuvB), which has long been implicated in the repression of cell
7

cycle-dependent genes53,54. The activation of p53 induces p21 expression, which subsequently
inhibits CDK, resulting in the hypophosphorylation of p107 and p13055,56. The incorporation of
hypophosphorylated p107 and p130 into the DREAM complex represses the transcription of many
cell cycle-regulated genes, such as CCNB1, CDC20, CDK1, and NEK257. Other potential mediators of
p53 gene suppression are non-coding RNAs. Mir-34, lincRNA-p21, and PANDA are induced by p53
and suppress the translation of their targets58-60. In short, p53-p21-DREAM and p53-induced noncoding RNAs, rather than direct repression of gene transcription, are major mediators of gene
repression by p53.

Figure 2 p53 target genes and associated cellular processes.
Most p53 target genes are transcriptionally regulated by p53. They are involved in a variety of cellular
activities, such as cell cycle arrest, apoptosis, senescence, metabolism, ferroptosis, Hippo pathway,
epigenetic regulation, and p53-mediated gene repression.
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1.2 p53 mutation and rescue
1.2.1 Mutant p53 overview
Since TP53 mutation occurs in ~50% of cancer cases with 100% coverage of cancer types,
TP53 is considered one of the most commonly mutated genes in human cancer61. Li-Fraumeni
syndrome patients with germline p53 mutations are susceptible to a wide range of cancers. Wt p53
forms tetramer to interact with consensus sequence, while misfolded or unfolded mutant p53
proteins are prone to amyloid-like aggregation, leading to loss of p53 functions and degradation
resistance. As shown in Figure 3, cancer-associated TP53 mutations occur at various sites within the
coding sequence but distribute unevenly, with a strong predominance in DBD of p5362. There exist 6
“hotspot” mutation residues (R175, G245, R248, R249, R273, and R282) in cancers62. Arg248 and
Arg273 mutations primarily impair p53 DNA contact without affecting wt p53 structure, whereas
Arg175, Gly245, Arg249, and Arg282 mutations principally distort the conformation of p5363,64.
Another group of p53 mutations, including V143A, Y220C, and F270L, are named temperaturesensitive p53 mutations. They cluster in beta-strands of DBD and destabilize p53, but not as severely
as conformational mutants. Interestingly, temperature-sensitive mutations are inactive at 37 degrees
Celsius, but regain transcriptional activity at 32 degrees Celsius due to improved stability and
refolding of DBD65.
1.2.2 Mutant p53 gain of function (GOF)
Unlike other tumor suppressor genes that usually undergo deletions or truncating mutations,
TP53 is often missense mutated, which leads to the substitution of only one amino acid in the
polypeptide sequence. High frequency of hotspot p53 mutations in tumors also suggests a growth
advantage of tumor cells with hotspot p53 mutations. Levine et al. reported the first observation of
mutant p53 GOF, showing the cooperation of mutant p53 with Ras oncogene in the transformation

9

Figure 3 TP53 mutation types and codon distribution.
(A) Pie chart of TP53 mutation types. (B) The histogram of mutations across TP53. Mutations are displayed
at the amino acid level across the full length of the polypeptides. The height of the bar represents the
percentage of the codon where the mutation occurred. Codon labeled if superior to 2%. Data are retrieved
from the IARC TP53 database (http://p53.iarc.fr/).
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of cells66. The following studies revealed a dominant-negative effect of mutant p53 that partially
accounts for mutant p53 GOF. Mutant p53 interacts with other members of p53 family, including p63
and p73, and inhibits their function. For example, mutant p53 regulates Dicer expression and thereby
blocks the biogenesis of tumor-suppressive miRNA through the interaction with TAp63, contributing
to tumor metastasis67.
However, mutant p53 can exhibit other oncogenic GOF in addition to TAp63 inhibition. For
instance, mutant p53-expressing mice showed more potent tumor invasion and metastasis than the
loss of TAp6368. The increased interaction of mutant p53 with other transcriptional factors, including
SREBP, Sp1, ETS, and NF-Y, plays an essential role36,69-71. For example, mutant p53 binds to ETS2 and
facilitates the transcription of TDP2, contributing to etoposide resistance of lung cancer cells70.
Mutant p53 also binds to and protects Stat3 from SHP2 phosphatase, leading to the activation of the
Jak2-Stat3 pathway in human colorectal cancer cells72. Importantly, the inhibition of HSP90, an
essential stabilizer of mutant p53, successfully suppresses mutant p53 level and tumor growth,
suggesting that mutant p53 GOF is a druggable target72.
Mutant p53 is also capable of promoting cell proliferation and tumor growth through the
regulation of genome-wide histone methylation and acetylation. The interaction of mutant p53 with
ETS2 upregulated expressions of methyltransferases and acetyltransferase. Genome-wide
upregulation of histone methylation and acetylation contributed to mutant p53 GOF73. Thus, genetic
knockdown and pharmacological inhibition of methyltransferases inhibit cancer cells harboring
mutant p53 growth significantly73. Similarly, mutant p53 increases H3K27me3 level through
interaction with EZH2, driving hematological neoplasm associated clonal hematopoiesis74. In
summary, mutant p53 GOF contributes to tumorigenesis through various mechanisms, providing a
novel target for personalized cancer treatment.
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1.2.3 Mutant p53 rescue
Increasing evidence suggests that all p53 mutations are distinct. Li-Fraumeni patients with
R248Q mutation demonstrated substantially worse prognosis when compared to patients with
G245S mutation, and similar results were observed in mutant p53 KI mice75. The consequence of a
single mutation is determined by the location of the residue and nature of the substitution. In
particular, R273C and R273H mutations only remove a guanidinium group that contacts with the
DNA backbone at the center of the p53-DNA interface with intact overall structure, whereas R175H
mutation disrupts zinc coordination sphere and the salt bridge with D184, leading to a global
unfolding of DBD76,77. The R175H mutation severely distorts p53 structure, whereas the mutation of
arginine to amino acids with smaller side chains, such as alanine or cysteine, is much less detrimental
with only moderate or no effect on p53 transcriptional activity63,78. Thus, the consequence of p53
mutation is dependent on mutant residue and substitution.
Since p53 mutations are prevalent in tumors, it is appealing to reactivate p53 tumorsuppressive activities in tumors harboring p53 mutations. According to in vitro experiments, the
introduction of a secondary mutation appears to rescue the mutations that destabilize p53 global
folding. For instance, H168R is a specific intragenic suppressor mutation for R249S, mimicking the
role of R249 in wt p5379. The introduction of H168R to R249S recovers the conformation of L2 and
L3 in wt p53 and thereby rescues the DNA binding of R249S mutation. In contrast, N239Y and N268D
mutations are global suppressor mutations that increase the thermodynamic stability of p53 DBD,
rescuing a subset of p53 mutations with unstable DBD structure80,81. The first successful screening of
mutant p53 rescuing compounds identified CP-31398, which increases the amount of p53 with wt
conformation in cells harboring mutant p53 and inhibits the growth of tumors with mutant p5382.
However, studies suggest that CP-31398 is a DNA intercalator, lacking direct binding or stabilization
of mutant p53, and induces ROS dependent cell apoptosis irrespective of p53 status83,84. The
distortion of DNA double helix by DNA intercalators interferes with DNA replication, transcription,
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and repair, resulting in off-target cell toxicity in cells83. Cells with loss-of-function mutant p53
manifest higher sensitivity to DNA intercalators since p53 is an essential mediator of DNA damage
repair response.
The alkylating agents PRIMA-1 and its methylated form APR-246 were identified as mutant
p53 activators in a cell-based screening85. They appear to induce p53 target gene expression and p53mediated apoptosis in cancer cells with mutant p5385,86. Apr-246 is useful for cancer treatment as a
single agent and in synergy with chemotherapeutic agents, such as cisplatin and doxorubicin87.
Mechanistically, PRIMA-1 and its analogs are metabolized to the active metabolite, 2-methylene 3quinuclidinone (MQ) in vivo. MQ then covalently modifies the thiol group of cysteine residues in
proteins via Michael reactions88,89. Similar reactions were identified in other alkylating agents,
including STIMA-1 and CP-3139888. The covalent modification of thiol groups in mutant p53 restores
wt conformation, which is at least partially responsible for the reactivation of mutant p5388.
Reactivation effects of mutant p53 via alkylating agents vary depending on tumor models and
mutation types. Interestingly, DNA contact p53 mutants can also be activated by alkylating agents90.
Recent studies suggested that p53 is not the only substrate of Micheal reaction, and alkylating
compounds induce apoptosis by modulating ROS (regardless of p53 mutation status)91,92. As the first
mutant p53-reactivating compound entering clinical trials, APR-246 might benefit cancer patients
through multiple tumor suppressive mechanisms independent of p53 mutation93.
In principle, any compounds that only bind to folded p53 should promote the stabilization of
unfolded p53 and shift the folding equilibrium toward the folded p5394. However, searching for such
compounds is challenging as there are no binding pockets on the DBD of p53, a recent study identified
a transiently open pocket in the L1/S3 pocket for mutant p53 reactivation95. Another consideration
is that the binding of compounds to p53 might interfere with p53 interacting with DNA or other
transcriptional cofactors.
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An alternative approach is to develop agents that bind to and rescue mutant p53-specific
lesions. The development of X-ray crystallization and computer-assisted drug design have enabled
the structure-guided design of mutant p53-reactivating compounds, and the rescue of temperaturesensitive mutant Y220C is an excellent proof-of-concept study.96 The large-to-small Y220C mutation
leads to the loss of local hydrophobic interactions and thereby destabilizes p53 moderately without
affecting DNA binding surface97. The detailed crystal structure of Y220C reveals a mutation-induced
surface crevice that can be targeted by ligands98. The subsequent structure-based design identified
small-molecule stabilizers that can selectively bind within the subpocket and stabilize Y220C
mutant99. The carbazole-based compounds remarkably inhibit the aggregation of Y220C mutation
and upregulate p53 target genes. However, their p53 mutation-independent cellular toxicity at high
concentrations could be an adverse effect that damages normal cells99. In summary, the success of
Y220C mutant-activating compounds supports the reactivation of specific p53 mutations for cancer
treatment. A similar approach may be utilized to rescue other thermodynamically unstable p53
mutations.

1.3 MDM2 & MDMX function and inhibitors
1.3.1 MDM2 structure and function
Mouse double minute 2 (MDM2), a conserved protein with 491 amino acids, is the primary
negative regulator of p53. Two upstream promoter sequences are responsible for the transcription
of MDM2, including a p53 responsive-element. MDM2 belongs to the RING finger domain family of
E3 ubiquitin ligases with four domains, including an N-terminal p53 binding domain, a central acidic
domain, a zinc finger, and a C-terminal RING domain. MDM2 N-terminal domain forms a hydrophobic
pocket for p53 interaction, inhibiting p53 activity. MDM2 also translocates p53 from the nucleus to
the cytoplasm. MDM2 central acidic domain is critical for p53 degradation, MDM2 mutant lacking
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part of this domain can ubiquitinate p53 but fails to degrade it100. The high degree of intrinsic
disorder of this region provides the flexibility to interact with most MDM2 regulating proteins, such
as ARF, ribosomal protein L5, CBP/p300, and HAUSP101-105. The phosphorylation of serine and
threonine residues in the acidic domain also contributes to the regulation of MDM2, such as p-Ser269 by CHK2 following DNA damage106. The zinc finger domain between the acidic domain and the
C-terminal RING domain is critical for MDM2-ribosomal protein interaction and the stabilization of
p53 under ribosomal stress102,107. Mutations of zinc finger domain block MDM2-ribosomal protein
interactions, providing a viable strategy to p53 activate p53108. The C-terminal RING domain is not
only responsible for MDM2 oligomerization but also recruits ubiquitin-conjugating enzyme E2 that
covalently modifies p53 lysine residues, resulting in p53 degradation. Ataxia-telangiectasia mutated
(ATM) and CHK kinases phosphorylate serine residues in or close to the RING domains of both MDM2
and MDMX after DNA damage, leading to the destabilization or disruption of MDM2/MDMX
oligomers and therefore p53 activation.109,110

Figure 4 Human MDM2 structure.
From the N-terminus to C-terminus: p53-binding domain (p53 BD); nuclear localization sequence (NLS);
nuclear export sequence (NES); central acidic domain (AD); zinc finger domain (Zn); and RING finger
domain.

In addition to functioning as a negative regulator of p53, MDM2 is also a transcriptional target
of p53, forming a negative feedback loop. Overexpression or amplification of MDM2 is frequent in
tumors with wt p53. The rescue of embryonic lethality in Mdm2-deficient mice by biallelic deletion
of p53 established the role of MDM2 as a primary p53 regulator111. There are two principal
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mechanisms by which MDM2 inhibits p53: direct inhibition of transcriptional machinery via Nterminal MDM2 interaction with p53 and RING domain-mediated p53 ubiquitination. Interestingly,
different level of p53 ubiquitination leads to distinct consequences. Mono-ubiquitination exports p53
to cytoplasm while poly-ubiquitination targets p53 for proteasomal degradation112,113. Notably,
MDM2 self-ubiquitination results in a rapid self-degradation with a short half-life of 30 min. In cases
of ARF expression and DNA damage, MDM2 also promotes the degradation of its homolog, MDMX114.
Interestingly, a replacement of the RING domain with that of PRAJA1 disables the ubiquitination of
p53 but retained MDM2 self-ubiquitination115. Thus, the self-ubiquitination of Mdm2 is independent
of its activities towards p53. Additionally, our laboratory revealed an ubiquitination-independent
inhibition of p53 DNA binding by the MDM2 acidic domain, which binds to p53 DBD and induces p53
conformational change116.
1.3.2 MDMX structure and function
MDMX or MDM4, the homolog of MDM2, shares a high level of sequence similarity with MDM2.
The N-terminal MDMX binds to the transactivation domain of p53 as MDM2 and inhibits p53
transactivation activity117. The intrinsically-disordered acidic domain of MDMX shares little
homology with MDM2 and plays a vital role in MDMX regulation. Our laboratory has demonstrated
that the binding of MDMX acidic domain with Casein Kinase 1a (CK1α) leads to the phosphorylation
on serine 289 and enhances the suppression of p53 by MDMX118. Furthermore, tumor-derived CK1α
mutants E98K and D140A increased binding affinity to MDMX and further improved MDMXmediated suppression of p53119. Upon DNA damage, ATM-induced Chk2 activation leads to the
phosphorylation of serine on the acidic domain (S342, S367, and S403) and degradation of MDMX by
MDM2110,120. A secondary binding between MDMX-MDM2 acidic domains in the presence of ARF
stabilizes MDM2-MDMX heterodimer and contributes to the degradation of MDMX by MDM2121.
Although the lack of E3 ligase activity in the RING domain disables MDMX to degrade p53 like MDM2,
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MDMX forms heterodimers with MDM2 through the RING domain and stimulates the degradation of
p53 by MDM2122,123.

Figure 5 Human MDMX structure.
From the N-terminus to C-terminus: p53-binding domain (p53 BD); central acidic domain (AD); zinc
finger domain (Zn); and inactive RING finger domain lacking E3 ligase activity.

MDMX is overexpressed in 40% of tumor cell lines and correlates with the presence of wt p53
in tumors124. The rescue of embryonic lethality of MDMX-null mouse by concomitant p53 deletion

demonstrated the role of MDMX in p53 regulation125. Interestingly, the lethality of MDMX null mice
is due to a severe proliferation deficiency, rather than increased apoptosis in MDM2 null mice125. A
tissue-specific knockout mouse model demonstrated that MDM2 is universally important for
tumorigenesis in different cell types, whereas MDMX knockout only causes minor phenotypic
defects126. MDMX KI mice with RING domain deletion or mutations, which abrogate the formation of
heterodimers with MDM2, exhibit p53-dependent early embryonic lethality, demonstrating the
cooperation of MDM2 and MDMX in p53 regulation127,128. Furthermore, MDMX was found to be
essential for MDM2-mediated p53 poly-ubiquitination in vitro, acting as a potent activator of
MDM2129. Without MDMX, MDM2 only catalyzes p53 mono-ubiquitination even at extremely high
concentrations. Thus, MDMX and MDM2 cooperate to modulate p53 activity and stability.
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1.3.3 p53-independent functions of MDM2 and MDMX
Recent studies suggest MDM2 and MDMX exert other effects on tumorigenesis in a p53independent manner. Therefore, conventional molecules targeting MDM2-p53 and MDMX-p53
interactions will not counteract p53-independent oncogenic effects of MDM2 and MDMX130. It is
necessary to gain more insights into the p53-independent activities of MDM2 and MDMX.
MDM2 overexpression leads to spontaneous tumor formation in p53-deficient mice
suggested that MDM2 has p53-independent oncogenic function131. Following studies suggested
MDM2 dysregulates cell-cycle regulation and DNA replication by inhibiting Rb activity. Rb is an
important tumor suppressor that blocks G1-S cell cycle progression by binding to the E2F1
transcription factor. MDM2 counteracts the tumor-suppressive function of Rb by disrupting Rb-E2F1
interaction and targeting Rb for degradation132-134. Another p53-independent oncogenic function of
MDM2 is to interfere with Mre11–Rad50–Nbs1 (MRN) complex, an important mediator of DNA
double-strand break repair. MDM2-Nbs1 binding compromises genome stability by delaying DNA
double-strand break repair after ionizing irradiation135. Consistently, centrosome hyper
amplification and aneuploidy are observed in cells that overexpress MDM2136,137. Additionally, MDM2
binds to the catalytic subunit of polymerase ɛ and stimulates enzyme activity in vitro, which alters
DNA replication fidelity138. Taken together, MDM2 affects carcinogenesis independently of p53 via
dysregulated G1-S progression and impaired DNA damage repair.
MDMX shares several oncogenic mechanisms with MDM2. It also binds to Rb and promotes
Rb degradation in an MDM2-dependent manner139. MDMX-Nbs1 interaction also delays DNA damage
repair and increased genomic instability140. However, MDMX also suppresses spontaneous
tumorigenesis via the promotion of bipolar mitosis in p53 deficient mice141. It remains unclear
whether MDMX regulation of the MRN complex mediates the suppression of chromosome loss.
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Previously, our laboratory reported that the binding of CK1α, an important component of
Wnt pathway, to MDMX stimulates MDMX-p53 interaction and further inhibits p53 functions142.
Recent findings suggest the binding of MDMX to CK1α also interferes with CK1α kinase activities. The
SG mutation of a conserved WW domain in MDMX (W201S/W202G) disrupts MDMX-CK1α binding.
Myc transgenic mice with MDMXsg showed enhanced p53 activities as expected. However, SG MDMX
mice displayed early onset of B cell lymphoma with shorter survival than mice with wt MDMX. It is
possible that SG mutation impairs a p53-independent, tumor-suppressive activity of MDMX143. Of
note, the interaction with CK1a is MDMX specific, not shared with MDM2144. Taken together, MDMX
might exert p53-independent functions via the intervention of CK1α kinase; further investigation is
required to delineate its significance in tumorigenesis and drug development.
1.3.4 MDM2 inhibitors
There are two primary strategies to activate p53 through MDM2 inhibition: the disruption of
p53- MDM2 interaction, and the inhibition of Mdm2 E3 activity. The first successful attempt at MDM2
inhibition lead to the discovery of Nutlin-3a, a cis-imidazoline analog, in 2004. It displaces three key
hydrophobic residues (Phe 19, Trp 23, and Leu 26) in the amphipathic helix of p53 from the
hydrophobic cleft in the p53-binding domain of MDM2, resulting in p53 accumulation and
activation145. X-ray crystallography of the MDM2-p53 interaction paves the way for structure-based
drug development and leads to the identification of MI-219, which increases MDM2 binding affinity
to 5 nM with better bioavailability146. An advanced version of Nutlin-3a, RG7112, stabilizes p53 and
activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition of tumor
xenografts147. Of note, these Nutlin-like compounds exhibit minimal toxicity in preclinical
experiments, therapeutically treatments of Nutlin-3a and MI-219 are well tolerated in mice without
causing significant weight loss or other signs of toxicity. Phase 1 trial of RG7112 showed clinical
activities against relapsed or refractory leukemia via the induction of p53 target genes in leukemic
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cells with wt p53148. Alternatively, an E3 ligase inhibitor, HLI98, inhibits MDM2 E3 ligase activity and
activates p53, but relatively high off-target effects hinder clinical applications of HLI98149.
A critical problem of current MDM2 inhibitors is the accumulation of MDM2 when activating
p53, which could be detrimental to normal tissues. With proteolysis targeting chimera (PROTAC)
concept, Wang et al. designed MD-224, an MDM2 degrader compound, by linking an E3 ubiquitin
complex binding ligand to a previously reported non-degrading MDM2 inhibitor150,151. MD-224
displays a strong binding affinity to both MDM2 and cereblon, an adaptor protein in the E3 ligase
degradation system150. The addition of MD-224 efficiently depletes MDM2 and activates p53 in
human leukemia cells carrying wt p53, leading to cell growth inhibition and apoptosis induction150.
One dose of MD-224 induces a sustained p53 protein accumulation for more than 24 hours without
MDM2 accumulation in mice, but whether the continuous induction of p53 can result in a stronger
tumor-killing without affecting normal tissue needs further evaluation.
1.3.5 MDM2 & MDMX dual inhibitors
Despite the 50% similarity of p53 binding domains between MDM2 and MDMX, most of
MDM2-p53 blocking compounds do not inhibit MDMX-p53 interactions. Simultaneous deletion of
both MDM2 and MDMX induces higher p53 activity than MDM2 deletion alone in tissue-specific
knockout mice, leading to a hypothesis that complete activation of p53 requires the inhibition of both
MDM2 and MDMX152. Our laboratory previously identified pDI, the first peptide that simultaneously
inhibits p53 interactions with both MDM2 (IC50 = 10 nM) and MDMX (IC50 = 100 nM)153. The
introduction of pDI leads to p53 activation in vitro and p53-dependent tumor inhibition in vivo153. Of
note, the simultaneous inhibition of MDM2 and MDMX by pDI induces significant apoptosis in wt p53
containing cancer cells, whereas Nutlin only induces cell cycle arrest in most tumor cell lines154.
Structure-based rational optimization of pDI further increases its binding affinity to MDM2 and
MDMX by 5-fold155. Interestingly, all of the first generation MDM2 & MDMX inhibitors screened by
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phage display, such as pDI, PMI, and sMTide, show sequence similarity with the MDM2-binding
sequence of p53, which confirms their mechanistic displacement of p53 from MDM2 and
MDMX153,156,157. Aileron Therapeutics developed α-helical p53-stapled peptides as MDM2 & MDMX
dual inhibitors, aiming to achieve a better efficacy for p53 activation in MDMX overexpressing
leukemia cells by lowering unrelated serum-binding activity158,159. These peptides displayed
encouraging anti-tumor activity in phase 1 clinical trials by efficiently rescuing p53 from both MDM2
and MDMX160,161.

1.4 IDR and intramolecular interaction in p53 pathway
1.4.1 Overview
Intrinsically disordered region (IDR) is a group of polypeptides lacking stable structures
under normal physiological conditions and can quickly switch among broad conformational
dynamics162. The abundance of charged and polar amino acids, low ratio of hydrophobic amino acids,
and poor sequence complexity determined the characteristics of IDR. Post-translational
modifications and interactions with partners often lead to disorder-to-order transitions or
conformational changes of IDRs. Interestingly, the ratio of IDR in the proteome correlates with the
complexity of an organism, suggesting the importance of IDR in cell signalling and protein-protein
interactions. IDRs have been identified in more than 30% of human proteins. In structured domains,
hydrophobic residues are important for intramolecular structure stabilization. Instead, hydrophobic
residues in IDRs broaden intermolecular interfaces for potential interactions163. The regulation of
CREB-binding protein (CBP) by cyclic-AMP response element binding protein (CREB) is a wellstudied example of IDR involvement in cellular signalling transduction. The binding of G-proteincoupled receptors to ligands activates protein kinase A (PKA), which then phosphorylates the kinase-

21

inducible domain (KID) of CREB, resulting in an induced folding of the disordered KID into a helical
structure and the recruitment of CBP to specific promoters164.
Importantly, IDR in a multi-domain protein can interact with structured domains within the
same protein in an intramolecular manner. Intramolecular interactions provide an essential
regulatory strategy to modulate protein functions, such as enzymatic activity, subcellular location,
and ligand binding. The majority of IDR-mediated intramolecular interactions are auto-inhibitory.
For example, the phosphorylation of Rb by cyclin-dependent kinases promotes the formation of an
intramolecular interaction between the C-terminal region and the central pocket of Rb, leading to the
blockage of Rb transcriptional suppression activities165. Intramolecular interactions also exist in
transcriptional factors. ETS is a transcriptional factor family with characteristic winged helix-turnhelix ETS domain that is responsible for specific DNA binding. The inhibitory α-helices flanking the
ETS domain can form intramolecular contacts with the ETS domain to inhibit DNA binding166. The
regulation of these α-helices impacts ETS activities. Phosphorylation of the serine-rich region
enhances the inhibition of DNA binding by stabilizing the intramolecular interaction167. In contrast,
the binding of RUNX1 interferes with the intramolecular binding and therefore promotes ETS DNA
binding167,168.
1.4.2 IDR and intramolecular interactions in p53 regulators
Advances in computational biology allow us to predict the existence of IDRs based on amino
acid sequences. Because of structural flexibility, it is difficult to obtain X-ray crystallography of IDRs
for biophysical analyses. Nuclear magnetic resonance (NMR) plays a central role in the study of IDR
with additional advantage of showing dynamic interactions between IDR and its binding partners.
However, a significant limitation of NMR is the reduced molecular tumbling rate due to large size of
oligomers, such as p53 tetramers. To characterize the weak and transient intramolecular interaction
that is mediated by IDRs, our laboratory previously developed a fragment release assay (FRA) by
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inserting PreScission protease cutting sites into protein169. After the cleavage of the protein by
protease, the interaction among fractions can be studied by a “pull-down”-like method.

Figure 6 Prediction of IDR in MDM2 and MDMX.
The IDRs in MDM2 and MDMX are predicted by their amino acid sequences using the PONDR platform
(http://www.pondr.com/). The regions with PONDR Score higher than 0.5 are considered as IDR. The
results show 2 highly disordered regions in 100-200 and 380-420 amino acids in both MDM2 and MDMX,
respectively.

Both MDM2 and MDMX contain IDRs in their central AD (Fig.6). As mentioned before,
multiple phosphorylation sites in MDM2 AD provide binding sites for MDM2/MDMX regulatory
proteins170. Using FRA, our laboratory identified an intramolecular interaction between the MDM2
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AD and RING domain that stimulates the E3 ligase function of the RING domain169. The mutation of
the AD domain suggests the necessity of both acidic and hydrophobic residues for the intramolecular
binding. ARF binding or phosphorylation of the AD domain inhibits the degradation of p53 by MDM2
through disruption of the AD-RING interaction169. This study demonstrates a novel role of the AD as
an auto-activation domain in MDM2.
Conversely, the intramolecular interaction in MDMX, the homolog of MDM2, acts as an
autoinhibitory module. The MDMX N-terminal p53-binding pocket weakly interacts with its central
region (residue 195–205), mimicking p53 18-29 residues. The binding of CK1α to the MDMX central
region disrupts the intramolecular interaction and stimulates MDMX-p53 binding171. Instead, DNA
damage-induced phosphorylation inhibits MDMX-CK1α interaction, stabilizing the intramolecular
binding in MDMX and thereby activating p53171. MDMX-S is a shorter transcript of MDMX without
central and C-terminal regions. MDMX-S appears to be a more potent inhibitor of p53 than full-length
MDMX, which is possibly due to the lack of autoinhibitory intramolecular interaction172.
Recently, our laboratory identified another intramolecular interaction in MDMX between the
AD and RING domain that regulates MDMX nuclear import142. Point mutation of 2 highly conserved
hydrophobic residues W200S/W201G (SG MDMX) disrupts the intramolecular binding of the AD to
both N- and C-terminal domains142. SG MDMX exhibited enhanced p53 binding affinity and nucleus
accumulation when compared to wt MDMX, which might be attributed to the disruption of
intramolecular interactions in MDMX142. In addition to disruption of the intramolecular interaction
in MDMX, CK1α also promotes a secondary interaction between MDMX AD and the core domain of
p53, leading to simultaneous inhibition of p53 DNA binding118. Thus, the AD domains of MDM2 and
MDMX mediate distinct intramolecular interactions. A full description of intramolecular interactions
in MDM2 and MDMX is shown in Figure 7. These novel interactions underscore the significance of
MDM2 and MDMX in p53 regulation, providing novel targets for drug development and biophysical
analysis.
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Figure 7 Intramolecular interactions in MDM2 and MDMX.
(A) The intramolecular interaction between the AD and RING domain in MDM2169. (B) The intramolecular
interaction between the AD and N-terminal p53 binding domain in MDMX171. (C) The intramolecular
interaction between the AD and RING domain in MDMX142.

1.4.3 IDR and intramolecular interactions in p53 CT
p53 can be roughly divided into three components: NT, core DBD region, and CT. NT is
responsible for the association with common transcriptional cofactors. Core DBD binds to specific
promoter sequences, and pathological mutations in this region often lead to the loss of specificity in
p53 DNA binding. CT binds to DNA without specificity and regulates p53 DNA binding. Both NT and
CT of p53 contain IDRs (Fig.8). Emerging evidence indicates the involvement of IDRs in the regulation
of p53173,174.
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Figure 8 Prediction of IDR in p53.
The prediction of IDR is processed with p53 amino acid sequences on PONDR website. The regions with
PONDR Score higher than 0.5 are considered as IDR. The results show 2 highly disordered regions in NT
and CT of p53.

The IDR at the very end of p53 CT has been extensively studied as an example of p53
autonomous regulation5. The CT is critical for p53 interaction with DNA substrates. The electrostatic
contacts between positively charged lysine and arginine residues and the phosphate backbone of
DNA confer non-specific DNA binding of p53 CT175. CT deletion impairs sequence-specific
interactions of p53 with both non-linear and linear DNA176. The deletion of CT 24 amino acids impairs
the induction of p53 target genes and thereby reduces p53 tumor suppression activities177. To
efficiently recognize its cognate sequence, p53 needs to search along genomic DNA with an optimal
affinity for nonspecific DNA. A single-molecule characterization of p53 suggested that CT is capable
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of rapid sliding along DNA, whereas the p53 DBD quickly binds to and dissociates from DNA via a 3D
hopping mechanism178,179. The authors further hypothesized that the cooperation of CT and DBD
enables efficient screening of p53 cognate sequences within genome DNA.
p53 CT is subject to multiple post-translational modifications, including phosphorylation,
methylation, acetylation, and ubiquitination. The 6 lysine residues in p53 CT are subject to different
modifications, including methylation, acetylation, and ubiquitination. These modifications affect p53
stabilization, DNA-binding activities, and cofactor recruitments. For instance, the competition of
lysine modification by MDM2-mediated ubiquitination vs. CBP/p300-mediated acetylation
determines p53 stability180. The identification of a secondary interaction between p53 CT with MDM2
NT highlights the significance of CT in p53-MDM2 binding181. Consistently, mice with CT-deleted p53
showed increased p53 level, anemia, bone marrow failure, and decreased lifespan, suggesting that
p53 CT may stabilize p53-Mdm2 interaction182,183.
6KR and 7KR p53 mutations are created to prevent CT lysine ubiquitination and acetylation
without affecting charge. Surprisingly, mice expressing 6KR or 7KR mutant p53 are different from
mice with CT-deleted p53, showing no significant changes in p53 stabilization and p53 function
under physiological conditions184,185. The CT might also promote the formation of pre-initiation
complex by interacting with many other cofactors after p53 binding to its cognate sequences. For
example, an important transcriptional regulator, BRD4, cooperates with p53 transcription activities
through the interaction with p53 CT46.
The effects of CT lysine acetylation on p53 DNA binding remains to be controversial. Initially,
the evidence from p300-mediated CT lysine acetylation suggested a positive effect on p53 DNA
binding104. Another study corroborated it by showing the acetylation of lysine residues on CT
augments p53 site-specific DNA binding and p53-mediated transcriptional activation in vitro186. On
the other hand, CT acetylation appears to repress p53 association with promoters since the complex
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of p53 with its targeted sequences destabilizes after single or multiple acetylation of p53 CT
residues176. Moreover, the treatment of Nutlin-3 showed a 6-fold higher occupancy of sequences by
p53 than the induction of doxorubicin51. Nutlin-3 is thought to increase p53 accumulation without
modifying p53, whereas doxorubicin causes multiple modifications of p53, including CT acetylation.
Acetylation of the CT is also necessary for TAF1 binding and phosphorylation of T55 residue in p53
NT, leading to the dissociation of p53 from promoters187. Thus, the role of CT acetylation in p53
regulation requires further investigation.
Although X-ray crystallography and NMR experiments have successfully revealed how the
p53 DBD binds to cognate DNA sequences, it is still a challenging task to biophysically analyze fulllength p53. Because of the conformational instability of the IDR, our structural understanding of the
p53 CT is limited. However, biochemical, structural, and MD studies have provided some valuable
information on the structure of p53 CT. Early data showed that DnaK, a chaperone protein, binds to
the CT of wt p53 but not denatured p53, protecting it from thermal denaturation, suggesting different
conformations of p53 CT188. A molecular dynamics study indicates that CT forms long-range
interactions with DBD and promotes conformational changes of p53 tetramers189. Another study
suggested that CT binds to the DBD of another p53 in the same tetramer to stabilize the tetrameric
state of p53 and to promote its transcriptional activity, which can be further enhanced by S392
phosphorylation190. In addition, a residue-specific limited proteolysis experiment demonstrated a
conformational change of the DBD by the CT in p53, which promotes the cooperativity of p53
tetramer and therefore enhances p53 specific DNA binding176. Notably, post-translational
modifications and interactions with other proteins alter the structure of the p53 CT. For instance,
K382-acetylated CT of p53 adopts a β turn-like conformation when bound to the bromodomain of
CBP after DNA damage191.
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1.4.4 IDR and intramolecular interactions in p53 NT
As a transactivation region, the NT is important for p53 function. The induction of traditional
p53 target genes requires both TAD1 and TAD2. A natural isoform of p53 lacking the first 39 residues
(p44) forms tetramer with full-length p53 and inhibits p53 activities192. Overexpression of p44 in the
context of full-length p53 leads to growth suppression and accelerates aging in mice because of
abnormal IGF signaling193. Mechanistically, p44 modulates p53 transcriptional activity through
dominant-negative inhibition and the interference of MDM2 binding to p53 hetero-tetramers in doseand cellular-dependent manners.
The importance of the p53 NT as transactivation domains is evident, but its role as an IDR
remains elusive. TAD2 transiently samples helical secondary structure and folds into a stable
amphipathic helix upon binding to partners. For example, when interacting with the hydrophobic
surfaces of the TAZ domain in CBP, TAD1 and TAD2 fold to form short amphipathic helices194.
Additionally, phosphorylation sites of the NT, including S15, T18, S20, S33, and T55, are wellpositioned to make favorable electrostatic interaction with electropositive regions of TAZ domains,
providing insights into the structural basis of how phosphorylation of the NT residues promote p53p300 interaction194. Disordered TAD1 and TAD2 also bind synergistically to the KIX domain of p300,
and the binding affinities increase with phosphorylation of the NT residues195.
Early studies suggested multiple conformations of p53 tetramer and allosteric regulation of
p53 by the NT. The binding of p53 antibody Pab1801 to the NT promotes both wt and temperaturesensitive mutant p53 DNA binding by stabilizing the active conformation of p53196,197. Deletion of the
NT also stimulates p53 DNA binding in vitro, but the mechanism is not clear197. With the application
of cryoelectron microscopy, the first 3D structure of a p53 tetramer suggested a direct connection
between NT and CT of monomers, which contributes to the structural plasticity of p53 tetramers198.
Single-molecule fluorescence resonance energy transfer (smFRET) technology enables the study of
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NT conformational dynamics in the context of p53 tetramer. It revealed a weak association between
the NT and DBD of p53199. Importantly,

13C-methyl

NMR spectroscopy identified a slow

conformational change of the NT that is modulated by specific recognition of DNA, suggesting an
allosteric regulation by the p53 NT174. Molecular dynamics simulation of full-length p53 monomer
also predicted direct hydrogen bonds between TAD2 residues and core DBD, which could be critical
for the maintenance of p53 conformation200. Although these studies implied the interaction of the
p53 NT and DBD, it requires further characterization in the context of p53 tetramer as well as
biological verifications.
Recent studies demonstrated a dynamic interaction between NT and DBD of p53, providing
shreds of evidence for allosteric regulation of p53 DNA binding201,202. Krois et al. generated segmental
labeling of 15N-p53 NT (1-61) in full-length p53 construct with a trans-intein splicing method so that
only the resonances of the p53 NT are visible within the tetramer in NMR spectroscopy201. The
dynamically disordered NT fluctuates freely between multiple states and makes transient contacts
with DBD of p53. TAD1 and TAD2 both interact with DBD, but TAD2 residues appear to be the major
component of the interaction with larger chemical shift perturbations201. Notably, these interactions
impair the binding of p53 to nonspecific DNA sequences, leading to an enhanced discrimination
between cognate and non-cognate sequences201. Krois’s work provided valuable high-resolution
evidence on NT-DBD interaction in p53 tetramer. However, a potential drawback of the study is the
lack of intrinsically disordered PRR of NT in 1-61 p53 NT labeling.
Our study also demonstrated an intramolecular interaction between the p53 NT and DBD.
Using 15N-labeled 1-312 p53, we showed that PRR residues also undergo significant chemical shift
changes upon DNA binding. We also confirmed the significance of the NT in p53 DNA binding,
showing that the NT inhibits p53 DNA binding in vitro and in vivo but increases p53 DNA binding
specificity202. According to Krois’s report, NT-DBD interaction in p53 depends heavily on electrostatic
forces that can be inhibited by increasing salt concentration, which is substantially different from
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p53-MDM2 interactions mediated by the hydrophobic pocket179,201. Consistently, we also observed
significant chemical shift perturbation of T55 residue in NMR spectroscopy upon DNA binding202. We
further found that T55 phosphorylation enhances NT-DBD interaction, but the underlying
mechanism remained unclear. T55 phosphorylation could promote electrostatic binding by
increasing the negative charge of TAD2 or fosters the formation of α-helix through a disorder-toorder transition of TAD2202. Interestingly, the phosphorylation of T55 leads to the dissociation of p53
from DNA, which could be due to an increased inhibitory effect on p53 DNA binding resulting from
the strengthened intramolecular NT-DBD interaction187.
The identification of NT-DBD interaction in p53 might help elucidate the effects of multiple
NT binding proteins, which allosterically regulate p53 under different cellular conditions. For
example, transcriptional coactivator 4 (PC4), high mobility group B1 (HMGB1), BRCA2, and
replication protein A complex (RPA70) interact with the IDR of TAD2, mimicking single-stranded
DNA203-206. They all induce the formation of an amphipathic helix in TAD2 upon binding, but the
biological effects vary. PC4 and HMGB1 enhance p53 binding to sequence-specific DNA, whereas
RPA70 and BRCA2 are negative p53 regulators. The functional difference is at least partly due to the
competition among other transcriptional cofactors and DNA bending207.
Considering the presence of NT-DBD interaction in p53, PC4 and HMGB1 might promote p53
functions by interfering with NT-DBD interaction. Other p53 NT binding partners might affect p53
functions in a similar mechanism of p53 allosteric regulation. Intriguingly, the binding of the NT to
HMGB1 also negatively regulates the HMGB1/Beclin1 complex, leading to the inhibition of autophagy
and survival of tumor cells208. Thus, the concept of IDR extends the role of p53 NT from a
transactivation domain to an allosteric regulator, shedding light on the mechanism of p53
posttranslational modifications and p53 interaction with binding proteins.
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The PRR is essential for p53 function. In terms of its structural role, the polyproline II (PPII)
structure in PRR exhibits rigidity and projects NT away from core domain209. The polymorphism of
p53 codon 72 with either proline (P) or arginine (R) alters p53 function and predicts cancer risk in
certain types of cancer. According to previous studies, R72 variant induces more robust apoptosis
than P72, and cancer patients with R72 genotype show elder age of onset with better survival210,211.
Recent studies linked the P72 variant to metabolism and longevity since P72 mice are less likely to
succumb to obesity and metabolic dysfunction212,213. However, the mechanisms behind these
functional alterations are not well understood. The R72 variant appears to exhibit more positive
charges in NT, which diminishes its single-strand DNA simulation effects and intramolecular
interaction. In contrast, the P72 variant exhibits more PXXP structure for SH3-containing proteins
binding. Furthermore, the polymorphism of codon 72 might change the rigidity of linker strain
between the intrinsically disordered TAD2 and the structured DBD of p53 and thereby affect the
intramolecular NT-DBD interaction. Thus, the effects of the p53 codon 72 polymorphism on
intramolecular NT-DBD interaction might account for the above-mentioned functional alterations.

Figure 9 p53 intramolecular interactions.
p53 NT interacts with DBD in an intramolecular manner or with DBD of other p53 within the same
tetramer. The NT-DBD interaction inhibits p53 DNA binding affinity but increases specificity. Posttranslational modifications of p53, such as phosphorylation of residues in p53 NT, modulate NT-DBD
interaction and allosterically regulate p53 functions. p53 binding partners, such as MDMX and HMGB1,
bind to p53 and interfere with NT-DBD interaction, altering p53 DNA binding activities.

32

CHAPTER 2 INTERACTION BETWEEN P53 N TERMINUS AND CORE DOMAIN REGULATES
SPECIFIC AND NONSPECIFIC DNA BINDING
2.1 Abstract
The p53 tumor suppressor is a sequence-specific DNA-binding protein that activates gene
transcription to regulate cell survival and proliferation. Dynamic control of p53 degradation and DNA
binding in response to stress signals are critical for tumor suppression. The p53 N-terminus (NT)
contains two transactivation domains (TAD1, TAD2), a proline-rich region (PRR), providing sites for
post-translational modifications and protein interactions. Previous work revealed the p53 NT
reduced DNA binding in vitro. Here, we show that TAD2 and PRR inhibit DNA binding by directly
interacting with the sequence-specific DNA-binding domain (DBD). NMR spectroscopy revealed that
TAD2 and PRR interact with the DBD at or near the DNA binding surface, possibly acting as a nucleic
acid mimetic to competitively block DNA binding. In vitro and in vivo DNA binding analyses showed
that the NT reduced p53 DNA binding affinity but improved the ability of p53 to distinguish between
specific and nonspecific sequences.

2.2 Introduction
The p53 tumor suppressor protein plays a critical role in regulating proliferation, cell death
and differentiation. p53 is activated by a plethora of cellular stress such as DNA damage, oncogene
activation, replicative stress, and hypoxia214. The activation process involves post-translational
modifications that suppress p53 degradation by MDM2 and increase p53 DNA binding affinity. Once
activated, p53 tetramers bind to responsive elements within genomic DNA to regulate the
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transcription of numerous target genes that orchestrate stress tolerance, DNA repair, cell cycle arrest,
apoptosis, and tumor suppression215. p53 is mutated in around 50% of human tumors, with higher
frequency in specific tumor types and after relapse. Mutated p53 loses transcriptional activity and
gains new functions that drive tumor progression216.
The p53 polypeptide can be divided into distinctive structural and functional domains. The
NT 90 residues contain two transactivation domains (TAD1: 1-40; TAD2: 40-60) and a proline-rich
region (PRR: 60-90). TAD1 also contains the main binding site for MDM2 and MDMX. TAD2 is
involved in transcription activation and protein interactions such as with RPA. Mutations in both
TAD1 and TAD2 are needed to eliminate the tumor suppressor function217. TAD1 and TAD2 also
contain multiple phosphorylation sites that regulate p53 degradation and activity during stress
response. Mutations or deletions in the PRR compromise p53 degradation, transactivation, apoptosis,
growth suppression, and tumor suppression218. The central DNA binding core domain (DBD: 94-312)
is required for sequence-specific DNA binding and is the target of most point mutations in cancer.
The C-terminus (CT, 312-393) contains an oligomerization domain (323-355) and a lysine-rich C
terminal tail (364-393) that harbors sites for acetylation, methylation, and phosphorylation.
Stress response by p53 is dependent on intricate mechanisms that regulate its amount and
activity. The MDM2/MDMX feedback loop plays a pivotal role in controlling the cellular level and
transcriptional activity of p53219. MDM2 binds to p53 NT to promote p53 ubiquitination and
degradation in the absence of stress. Both MDM2 and MDMX have central acidic domains that engage
in second-site interactions with p53 DBD and inhibit DNA binding116,118. Additionally, the
phosphorylation of p53 on NT residue T18 inhibits MDM2 binding220,221. DNA damage-induced
phosphorylation of MDM2 inhibits its dimerization and E3 ligase activity, which also contributes to
the accumulation of p53222.
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Both NT and CT of p53 have high degrees of intrinsic disorder. The p53 CT has welldocumented effects in regulating DNA binding. The CT antibody Pab421 stimulates DNA binding by
p53 in EMSA. Acetylation of CT by p300/CBP stimulates specific DNA binding in vitro223. Analysis of
p53 mutants suggests that the C-terminal tail is important for binding and activation of target genes
with sub-optimal binding sites176. The C-terminal tail engages in intersubunit interaction with the
DBD and stimulates p53 oligomerization190. The CT is capable of nonspecific DNA binding and
enabling p53 to slide on DNA, which is an important step in the search for specific binding sites178.
Mouse models that delete the C-terminal tail caused p53 stabilization and over-activation, resulting
in developmental abnormalities182,224.
The p53 NT performs several important functions. TAD1 and TAD2 interact with basal
transcription factors such as TBP, TFIID, and coactivator p300/CBP. NT phosphorylation after DNA
damage stimulates recruitment of p300/CBP that in turn acetylates the CT221. The NT was also
implicated in suppressing sequence-specific DNA binding by the DBD197. Antibody binding to the NT
changed the thermostability of the DBD, suggesting that the NT participates in DBD folding or is part
of the final structure225. Deletion of the PRR alone stimulated DNA binding in vitro226. A singlemolecule FRET study suggests the NT weakly interacts with the DBD199. Intramolecular interaction
between the DNA binding domain and adjacent regulatory domains were found to have autoinhibitory roles in other DNA binding proteins227.
In this report, we provide evidence that the p53 NT interacts with the DNA binding site in the
DBD via the TAD2 and PRR modules. The interaction not only reduces overall DNA binding affinity;
importantly, it also increases p53 selectivity for specific DNA in vitro and in vivo. The findings
corroborate a recent in vitro analysis and provide new insight into p53 regulation by NT
modifications and binding proteins201.
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2.3 Methods and Materials
2.3.1 Plasmids and cell lines
The p53c1 construct contains the sequence LEVLFQGPG inserted before p53 residue 90,
which allows removal of residue 1-89 by cleavage with PreScission protease. The p53c2 construct
contains LEVLFQGPYPYDVPDYA and LEVLFQGPEEQKLISEEDL inserted before p53 residues 90 and
299, respectively. The GST-PreScission protease fusion protein was purified from E. coli by
glutathione agarose column. p53 deletion mutants are generated by PCR amplification and
subcloning. Point mutations in the p53 coding sequence are introduced through in vitro site-directed
mutagenesis. pLenti4/V5-DEST Gateway vector is used for cloning and high-level expression of genes
of interest in mammalian cells. Cell lines H1299 (p53-null), H1299 tet-on, U2OS (wt p53), and H1299
with inducible p53 were cultured in Dulbecco’s modified Eagle medium (DMEM) with 10% (vol/vol)
fetal calf serum at 37 ˚C in a 95% air, 5% CO2 humidified incubator.
2.3.2 Proteolytic fragment release assay
H1299 cells were transiently transfected with p53c1 or p53c2 plasmid by standard
polyethylenimine (PEI) transfection (Polysciences). Cells were lysed with lysis buffer [150 mM NaCl,
50 mM Tris⋅HCl pH 8.0, 0.5% Nonidet P-40, 5 mM EDTA, 0.5 mM DTT]. Cell lysate from ∼ 2 x 106 cells
(a 10 cm plate) was incubated with 20 μl of packed protein A beads with chemically cross-linked
FLAG or Myc mouse monoclonal antibodies for 18 h at 4˚C. The beads were washed 2 times with
PreScission buffer (150 mM NaCl, 10 mM HEPES pH 7.5, 0.05% Nonidet P-40, 0.5 mM DTT, and 10%
glycerol) and suspended in 200 µl PreScission buffer. PreScission protease was added to 0.1 µg/µl
final concentration, and the beads were incubated at 23˚C with shaking for 10–30 min. The digestion
mixture was centrifuged for 10 sec, and the beads (bound material) and supernatant (released
material) were separated. The beads were washed once with PreScission buffer. The beads and
supernatant were boiled in Laemmli sample buffer [4% (wt/vol) SDS, 20% glycerol, 200 mM DTT,
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120 mM Tris (pH 6.8), 0.002% bromophenol blue] and analyzed by SDS/PAGE and WB using FL393
or HA tag antibodies to determine the bound/released ratio of each fragment.
2.3.3 Purification of p53 and DNA affinity immunoblotting
H1299 cells were transiently transfected with FLAG-tagged p53 using PEI method. Cells from
a 10-cm dish were lysed in 1 ml lysis buffer, centrifuged for 10 min at 14,000 g, and the insoluble
debris was discarded. The lysate was incubated with 30 µl slurry of anti-FLAG M2-agarose beads
(Sigma) for 18 h at 4˚C. The beads were washed with lysis buffer, FLAG-p53 was eluted with 200 µl
lysis buffer containing 200 µg/ml FLAG epitope peptide (Sigma) for 2 h at 4˚C. An aliquot of the eluted
proteins was analyzed for expression levels by WB. Lysate containing equal level of p53 was added
to a 200 µl DNA binding reaction mixture and incubated at 4˚C for 30 min. The DNA binding reaction
contains 25 nM (0.01 nmol) double-stranded biotinylated oligonucleotide DNA containing a
consensus p53 binding site (Biotin-5’-TCGAGAGGCATGTCTAGGCATGTCTC-3’ annealed to
5’GAGACATGCCTAGACATGCCTCTCGA-3’), 2 µg poly(dI-dC), 5 mM DTT, 150 mM NaCl, 20 mM
Tris⋅HCl (pH 7.2), and 4% glycerol. Mutant control oligonucleotide contains Biotin-5’TCGAGAGGTCGCTCTAGGTCGCTCTC-3’ annealed to 5’-GAGAGCGACCTAGAGCGACCTCTCGA-3’. The
DNA/protein complexes were captured with 0.1 mg magnetic Streptavidin beads (Promega) at 4˚C
for 30 min. The beads were collected using a magnet and washed two times with DNA binding buffer.
The bound p53 was eluted by boiling in Laemmli sample buffer and analyzed by SDS/PAGE and WB
using FL393 antibody. Following peptides are used in p53 DNA affinity immunoblotting: 48-62
(DDIEQWFTEDPGPDE), SCR 48-62 (PIDPDWETDGEQDFE), 75-89 (PAPAAPTPAAPAPAP), SCR 75-89
(PPPPPPPTAAAAAAA), Control1 (KPLQSTANNTPK), and Control2 (HQNKSNLSSGLM).
2.3.4 Chromatin immunoprecipitation (ChIP)
Cells from 2 confluent 15-cm dishes were cross-linked by adding formaldehyde directly to
the media to a final concentration of 0.75% and rotate gently at room temperature (RT) for 10 min.
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Glycine was added to the media at a final concentration of 125 mM with shaking for 5 min. Cells were
rinsed twice with cold PBS, collected and resuspend in RIPA Buffer ( 50 mM Tris-HCl pH 7.4, 150 mM
NaCl, 1% Triton X- 100, 0.1% sodium dodecyl sulphate (SDS), 1% sodium deoxycholate) on ice. To
shear DNA to an average fragment size of 200–1000 bp, lysate was sonicated for 60 min with 30s-on,
30s-off program. After sonication, cell debris was removed by centrifugation. Samples were precleared with ssDNA incubation and diluted 1:10 with ChIP dilution buffer (0.01% SDS, 1% Triton X100, 1.2mM EDTA, 16.7mM Tris-HCl pH 8, 167mM NaCl). The diluted samples were separated for the
specific

antibody

immunoprecipitation

(Pab421

or

DO-1

antibody

for

p53),

control

immunoprecipitation (Mouse IgG) overnight and inputs (1:50). Immunoprecipitated samples were
centrifuged for the following washes in turn: once in low salt wash buffer (0.1% SDS, 1% Triton X100, 2mM EDTA, 20mM Tris-HCl pH 8, 150mM NaCl), once in high salt wash buffer (0.1% SDS, 1%
Triton X- 100, 2mM EDTA, 20mM Tris-HCl pH 8, 500mM NaCl), once in LiCl wash buffer (250 mM
LiCl, 1% NP-40, 1% NaDOC, 1mM EDTA, 10mM Tris-HCl pH 8) and twice in TE buffer (1mM EDTA,
10mM Tris-HCl pH 8). Each wash was conducted on rotor rack for 5 min. DNA-protein complexes
were then eluted in 200 µl fresh-made ChIP elution buffer (1% SDS, 100mM NaHCO3) with slow
vortex for 20 min. After sequential cross-link reversal and protein degradation with proteinase K,
DNA was purified using a PCR purification kit. DNA levels were measured by real-time quantitative
PCR.
Primer sets:
p21:
(Forward: 5’-AGGAAGGGGATGGTAGGAGA-3’, Reverse: 5’-ACACAAGCACACATGCATCA-3’).
MDM2:
(Forward: 5’-CGGGAGTTCAGGGTAAAGGT-3’, Reverse: 5’-CCTTTTACTGCAGTTTCG-3’).
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PUMA:
(Forward: 5’-CTGTGGCCTTGTGTCTGTGAGTAC-3’, Reverse: 5’-CCTAGCCCAAGGCAAGGAGGAC-3’).
Fas:
(Forward: 5’-ACAGGAATTGAAGCGGAAGTCT-3’, Reverse: 5’-GAGTTCCGCTCCTCTCTCCAA-3’).
LINE1:
(Forward: 5’-CAGAATCTCTGGGACGCATT-3’, Reverse: 5’-ATTGTGATGTTCGGGTGTCA-3’).
Alu:
(Forward: 5’-ACGAGGTCAGGAGATCGAGA-3’, Reverse: 5’-CTCAGCCTCCCAAGTAGCTG-3’).
alpha satellite D5Z1:
(Forward: 5’-TAGACAGAAATATTCTCACAATCGT-3’, Reverse: 5’-GCCCTCAAAGCGCTCCAAG-3’)
alpha satellite D5Z2:
(Forward: 5’-TTTTTGTGCAATTGGCAAATGGAG-3’, Reverse: 5’-AGACTGTTTCCTCACTGCTCT-3’)
2.3.5 Luciferase fragment complementation p53 DNA binding assay
To construct ZF-Nluc, luciferase 1-437 was fused to the C-terminus of a high affinity 6-finger
zinc finger and cloned into pET28 vector228. To construct p53-Cluc, luciferase 398-550 was fused to
the C-terminus of p53 and cloned into pET28. ZPBS double-stranded oligonucleotide (5’CCGATGTAGGGAAAAGCCCGGGAACATGTCCCAACATGTTGAGC-3’) contains zinc finger binding site
(5’-ATGTAGGGAAAAGCCCGG-3’. Kd = 50 pM) and p53 binding site from the p21 promoter (5’GAACATGTCCCAACATGTTG-3’. Kd = 5 nM). BL21DE3 cells transformed with p53-Cluc or ZF-Nluc
were cultured to OD600=0.6 at 37˚C, supplemented with 0.1 mM IPTG and 150 μM ZnCl2, and
cultured for 20 h at 16˚C. Pelleted E. coli cells were sonicated in lysis buffer [50 mM HEPES (pH 7.5),
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150 mM NaCl, 0.1% Nonidet P-40, 5% glycerol, 10 μM ZnCl2, 1 mM DTT] and centrifuged at 10,000 g
for 10 min at 4˚C. The lysate was diluted in dilution buffer [4.25% (vol/vol) 0.2 M NaH2PO4, 45.75%
(vol/vol) 0.2 M Na2HPO4, 5% glycerol, 1 μM ZnCl2, 1 mM DTT] to ~10 ng/µl total protein. The diluted
BL21DE3 extract (~200 ng) containing ZF-Nluc was mixed with 20 ng ZPBS oligo and 1% fetal bovine
serum and incubated at 23˚C for 15 min to allow ZF-Nluc pre-binding. BL21DE3 extract (~200 ng)
containing p53-Cluc was added to the mixture and incubated for 45 min at 23˚C to assemble active
complexes. Two µg of mutant ZPBS oligonucleotide without zinc finger binding site (5’CCGACGTCGGTAACAGTCCAGGAACATGTCCCAACATGTTGAGC-3’) was then added as competitors
and incubated at 23˚C. Luciferase substrates were added at different time points after the addition of
competitor for luciferase activity readout.
2.3.6 Western blot analysis (WB)
Total cellular protein was extracted using lysis buffer with 1% proteinase inhibitors cocktail
and 1% phosphatase inhibitors. After protein quantification with BCA method, samples were boiled
in Laemmli sample buffer. Equal amount of protein was loaded into wells of sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE; 12% polyacrylamide gels) along with molecular
weight marker. Gels were run for 1-2 hours at 100 V. Protein was transferred from gel to PVDF
membranes (Bio-Rad), blocked for 1 hour with PBS containing 0.1% Tween 20 (PBST) and 5%
(wt/vol) nonfat dry milk, and incubated with primary antibodies overnight at 4°C. After washing with
PBST for 3 times, membranes were incubated with HRP-conjugated secondary antibody for 1 hour
at room temperature and developed using Supersignal reagent (Thermo Scientific). The following
antibodies were used: FL393 (Santa Cruz) and DO-1 (BD Pharmingen) for p53 detection; FLAG
antibody (Sigma); and P21 antibody (BD Pharmingen).
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2.3.7 In vitro site-directed mutagenesis
The QuikChange II site-directed mutagenesis kit was used to create desired point mutations
in specific plasmids. Two complementary oligonucleotides containing the desired mutation were
synthesized for PCR amplification. The amplification reaction was prepared with 10 ng dsDNA
template and 2.5 U PfuUltra HF DNA polymerase. Cycling Parameters for the reaction were set
according to the QuikChange II site-directed mutagenesis kit (Agilent Technologies). Dpn I restriction
enzyme (10 U/µl) was applied to digest the parental template specifically. XL1-Blue super competent
cells were transformed with Dpn I-treated DNA. The fidelity of the mutagenesis was inspected with
DNA sequencing.
Primer sets:
S46D:
(Forward:

5’-GGATGATTTGATGCTGGACCCGGACGATATTGAAC-3’,

Reverse:

5’-

Reverse:

5’-

Reverse:

5’-

Reverse:

5’-

GTTCAATATCGTCCGGGTCCAGCATCAAATCATCC-3’)
S46A:
(Forward:

5’-GGATGATTTGATGCTGGCCCCGGACGATATTGAAC-3’,

GTTCAATATCGTCCGGGGCCAGCATCAAATCATCC-3’)
T55D:
(Forward:

5’-TATTGAACAATGGTTCGATGAAGACCCAGGTCCAG-3’,

CTGGACCTGGGTCTTCATCGAACCATTGTTCAATA-3’)
T55A:
(Forward:

5’-TATTGAACAATGGTTCGCTGAAGACCCAGGTCCAG-3’,

CTGGACCTGGGTCTTCAGCGAACCATTGTTCAATA-3’)
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P72R:
(Forward:

5’-GAATGCCAGAGGCTGCTCCCCGCGTGGCCCCTGCACCAGCAGC-3’,

Reverse:

5’-

GCTGCTGGTGCAGGGGCCACGCGGGGAGCAGCCTCTGGCATTC-3’)
S15D:
(Forward:

5’-CGTCGAGCCCCCTCTGGATCAGGAAACATTTTCAG-3’,

Reverse:

5’-

CTGAAAATGTTTCCTGATCCAGAGGGGGCTCGACG-3’)
T18D & S20D:
(Forward:

5’-GCCCCCTCTGGATCAGGAAGACTTTGACGACCTATGGAAACTAC-3’,

Reverse:

5’-

GTAGTTTCCATAGGTCGTCAAAGTCTTCCTGATCCAGAGGGGGC-3’)
2.3.8 Establishment of N-terminal truncated p53 mutants expressing H1299 cell lines
Full length or N-terminal truncated p53 were cloned into pLenti4/V5-DEST plasmid
according to ViraPower Gateway Kits manual. Genes were cloned into a Gateway entry vector to
create an entry clone. LR recombination reaction was performed to generate a p53 expression clone
with pLenti4/V5-DEST plasmid. LR recombination reaction products were transformed into One
Shot Stbl3™ Chemically Competent E. coli followed by miniprep DNA isolation and sequencing to
ensure the insert was correctly orientated and in-frame with the V5 epitope tag. ViraPower
Packaging Mix and the pLenti4/V5-DEST p53 expression construct were co-transfected into the
293FT producer cell line with Lipofectamine™ 2000 Reagent (Invitrogen). Viral supernatant was
harvested and filtered for infection of the H1299 tet-on cell line. p53 expression was conﬁrmed by
WB in the presence of doxycycline (a derivative of tetracycline).
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2.3.9 Protein purification for NMR and ITC
P53 NT 1-89 (72R) was expressed as previously described except using pET47 and
PreScission cleavage in place of pET28 and Thrombin229. The longer p53 ND (1-312) and p53 DBD
(94-312) were expressed in BL21 cells grown in M9 media. The cells were cultured at 37˚C until
OD600=0.5, ZnCl2 was added to 29 µM and the cultures were cooled to 15˚C for 30 min. IPTG (1 mM)
was added to induce expression for 18-20 hours at 15˚C. Cells were pelleted and frozen at -80˚C until
lysis. Cells were lysed in Tris-buffered saline (50 mM Tris-HCl, 500 mM NaCl, 1 mM DTT, 20 µM ZnCl2)
using a French press. Lysate was centrifuged and the supernatant was applied to a GE GST-fast flow
column and eluted with reduced glutathione. The eluate was cleaved with PreScission for 18 hours
and the glutathione was removed by dialysis. The DBD sample was concentrated and run on a GE
Superdex-75 column for final purification. The p53 ND construct was run through anion exchange
column using standard Tris buffer containing 20 µM ZnCl2 prior to final size exclusion
chromatography.
2.3.10 NMR data collection and analysis
NMR experiments were carried out at 25°C on a Varian VNMRS 800 MHz spectrometer
equipped with a triple resonance pulse field Z-axis gradient cold probe. Sensitivity enhanced 1H-15N
HSQ, 1H-15N HSQC-TROSY and three-dimensional HNCACB, HNCA-TROSY, and HNCO experiments
were performed on the uniformly

15N

and

13C-labeled

samples in 90% H2O/10% D2O, unless

otherwise stated the buffer was 10 mM phosphate buffer with 66 mM NaCl, 4 mM DTT, and 0.02%
NaN3, at pH 6.8. For the HNCACB experiment, data were acquired in 1H, 13C and 15N dimensions using
9689.9 (t3)  14074.9 (t2)  2754.4 (t1) Hz sweep widths, and 1024 (t3)  128 (t2)  32 (t1) complex
data points. For the HNCO, the sweep widths were 9689.9 (t3)  2010.4 (t2) 2754.4 (t1) Hz, complex
data points were 1024 (t3)  128 (t2)  32 (t1). The HNCA-TROSY was collected with 9689.9 (t3) 
6031.9 (t2)  2754.4 (t1) Hz sweep widths, and 1024 (t3)  128 (t2)  32 (t1) complex data points23043

233. The sweep widths and complex points of the HSQC were 9689.9 (t

2) 

2754.4 (t1) Hz and 1024 (t2)

 128 (t1), respectively. Relaxation experiments were collected using at least 10 time points from 10
ms up to 250 ms and fit to an exponential decay function using NMRViewJ234.
All 3D experiments were conducted with 140 to 200 µM samples. The 15N labelled p53 NT
relaxation data was collected at 250 µM, the p53 NT with 4x p53 DBD was conducted with 50 µM of
labelled NT titrated with 200 µM of unlabelled p53 DBD. The 15N labelled p53 DBD to unlabelled p53
NT was collected with 111 µM p53 DBD titrated with up to 666 µM NT. The relaxation data for the
p53 ND sample was collected at 200 µM of labelled ND. For the p53 ND HNCACB and HNCO, only
residues in the disordered p53 NT and toward the C-terminal were assignable resulting in 83 Ca, 82
Cb, 66 CO, and 67 HN and N assignments to the first 86 residues. The p53 DBD HSQC-TROSY, and
HNCA-TROSY assignments were made by comparing chemical shift values to those published by
Kriwacki235.
All NMR spectra were processed with NMRFx and analysed using NMRViewJ software236.
Apodization was achieved in the 1H, 13C and 15N dimensions using a squared sine bell function shifted
by 70. Apodization was followed by zero filling to double the number of real data points and linear
prediction was used in the 15N dimension. The 1H carrier frequency was set on the water peak, and
4.753 ppm was used as the reference frequency. Secondary chemical shift values were calculated by
subtracting the residue specific random coil chemical shifts in the neighbour-corrected IDP chemical
shift library (ncIDP) from the measured chemical shifts237. Secondary structure populations were
calculated with d2D using the measured proton, nitrogen, alpha and beta carbon, and carbonyl
carbon chemical shifts238.
2.3.11 Isothermal titration calorimetry (ITC)
p53 polypeptides and DNA were co-dialyzed into 10 mM NaPO4, 66 mM NaCl, 0.02% sodium
azide, 8 mM BME at pH 6.8. For p53 DBD constructs 3 replicate titrations were conducted with 5 µM
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p53 DBD in the cell and 12.5 µM of DNA in the syringe using 10 µl injections using a MicroCal-VP-ITC
system at 25˚C. For the p53 ND constructs 2 to 3 titrations were conducted using a MicroCal-ITC 200
system with 50 µM ND in the cell and 125 µM of DNA in the syringe using 15 µl injections at 25˚C. The
corrected heat values were fit using Microcal Origin software (7.0 built) in non-linear least square
curve-fitting algorithm yielding the stoichiometry, enthalpy, and affinity constants reported for a
single binding site. The following double-stranded DNA oligonucleotides were used: Consensus 5’AGACATGCCTAGGACATGCCT-3’ and scrambled 5’-TGCCGATCAAAACCGATTCG-3’239.
2.3.12 Statistical analysis
For two-group comparisons, Student’s t-test or paired t-test (two-sided) was applied.
Significance for multiple condition experiments was determined using one-way ANOVA. In the
figures, significance was noted using *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, not
significant. All data shown in the bar graphs were the mean ± SD of at least three biological replicates.
Statistical analysis was conducted using the Prism7 (GraphPad) software.

2.4 Results
2.4.1 The p53 NT interacts with the DBD
Previous studies showed that recombinant p53 with NT deletion (∆1-90) had increased DNA
binding in DNase I footprinting and EMSA assays197. Several antibodies against p53 NT epitopes can
stimulate DNA binding225. The p53 NT is an intrinsically disordered region that engages in numerous
protein-protein interactions, some of which are kinases that regulate p53 through
phosphorylation240. These studies suggested the possibility of a direct interaction between the NT
and DBD, but the absence of high-resolution structural studies to detect this interaction has left a
number of open questions 199,201. To test whether the NT interacts directly with the DBD, we used a
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Figure 10 Detection of p53 domain binding.
(A) Design of p53c1 and p53c2 constructs with Precision (PreS) cleavage sites and epitope tags (FLAG,
HA, and Myc). (B) Diagram of proteolytic fragment release assay. (C, D) p53c2 expressed in H1299 was
immobilized on FLAG or Myc beads and cleaved by PreScission for 30 min. The beads and supernatant
were analyzed for DBD fragment by HA WB. Pairwise quantitation is shown below the blots. (E) p53c1
was immobilized on FLAG beads, cleaved by PreScission, and analyzed for DBD fragment release by WB
using an antibody for full-length p53 (FL393). Pairwise quantitation is shown below the blots.

proteolytic fragment release assay for detecting weak intramolecular and intermolecular domain
interactions118,142. PreScission protease cleavage sites, followed by epitope tags, were inserted into
p53 to generate the p53c2 and p53c1 constructs (Fig.10A, 10B). PreScission cleaves p53c2 into 3
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fragments: FLAG-tagged 1-90, HA-tagged 91-299, and Myc-tagged 300-393. Cleavage of p53c1
produced FLAG-tagged 1-90 and untagged 91-393.
The p53c2 construct was expressed in H1299 cells, immobilized on beads, and cleaved with
PreScission. Interactions between fragments were interrogated by immobilizing p53c2 using
different antibodies and analyzing the retention/release ratio of each fragment by WB (Fig.10B).
Using this assay, the NT-DBD interaction (FLAG immobilization, Fig.10C) was significantly stronger
than the DBD-CT interaction (Myc immobilization, Fig.10D). A similar analysis using the p53c1
construct with a single PreScission site also showed significant NT binding to the 91-393 fragment
(Fig.10E). The results demonstrate the p53 NT directly interacts with the DBD.
2.4.2 Intersubunit interaction between the NT and DBD
p53 forms dimers and tetramers (dimer of dimer) mediated by the CT oligomerization
domain (325-356). To determine whether the NT-DBD interaction diagrammed in Fig.10 is
intramolecular or intermolecular, point mutations were introduced into p53c1 to disrupt
oligomerization (Fig.11A). The ALAL mutant forms dimers but not tetramers, whereas the KEEK
mutant is monomeric241. Analysis of the ALAL and KEEK mutants using the fragment release assay
showed the NT-DBD interaction was significantly reduced by the KEEK mutation but partially
restored in the ALAL mutant (Fig.11B), suggesting that the NT of 1 subunit preferentially interacts
with the DBD of another p53 with in the same dimer or with p53 in a different dimer. The result did
not rule out the weak intramolecular fold back interaction, which is structurally permissible based
on a crystallographic study242.
To confirm the interaction detected using the fragment release assay, GST-p53-1-90
produced in E. coli was used to pull down p53-90-393 expressed in H1299 cells. GST-p53-1-90 but
not GST pulled down p53-90-393 (Fig.11C). Further mapping performed using GST fusions of TAD1,
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TAD2, and PRR showed that TAD2 and PRR retain weak binding to p53-90-393, suggesting that both
regions participate in binding to DBD (Fig.11D).

Figure 11 Analysis of p53 domain binding.
(A) Diagram of wt, ALAL, and KEEK p53c1 constructs. (B) Wt, ALAL, and KEEK p53c1 expressed in H1299
were immobilized on M2 beads, cleaved by protease, and analyzed for DBD fragment release by WB using
p53 antibody FL393. (C) Lysate of H1299 transfected with FLAG-p53-90-393 was incubated with beads
loaded with GST or GST-p53-1-90. Pull-down of FLAG-p53-90-393 was detected by FLAG WB. (D) Lysates
of H1299 cells transfected with FLAG-p53-90-393 was incubated with glutathione beads loaded with GST,
GST-p53-1-90, GST-p53-1-40 (TAD1), GST-p53-35-65 (TAD2) and GST-p53-65-90 (PRR). Pull-down of
FLAG-p53-90-393 was detected by FLAG WB.
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2.4.3 p53 NT inhibits binding to DNA but increases DNA binding specificity in vitro and in
vivo

Figure 12 p53 NT inhibits DNA binding in vitro.
(A) Diagram of N-terminal truncated p53c1 mutants with C-terminal FLAG tag. (B) FLAG-tagged p53c1
mutants were immuno-purified from transfected H1299 cells, cleaved with protease, and incubated with
beads loaded with biotinylated oligonucleotide containing p53-binding site. The captured p53 was
detected by WB using FL393. The level of p53 input was confirmed by WB. (C, D) Purified p53c1 mutants
were cleaved with protease and incubated with immobilized biotinylated oligonucleotide in the presence
of antibodies. The captured p53 was detected by WB using FL393. Pairwise quantitation is shown below
the blots. (E) Purified FLAG-p53-90-393 was incubated with immobilized biotinylated oligonucleotide in
the presence of NT peptides (200 µM). The captured p53 was detected by FLAG WB. Quantitation is shown
below the blots. (F) FLAG-tagged p53c1 were immuno-purified from transfected H1299 cells, cleaved with
protease, and incubated with beads loaded with biotinylated oligonucleotide containing p53-binding site.
Protease cleaved samples were serially diluted for quantification. Non cleavable p53 samples were used
as controls. (G) Purified FLAG-p53-1-393 was incubated with immobilized biotinylated oligonucleotide in
the presence of NT peptides (200 µM). The captured p53 was detected by FLAG WB.
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Previous EMSA and DNase footprinting assays showed that p53-90-393 produced in insect
cells exhibits increased DNA binding in vitro197. To rule out effects from post-translational
modification caused by the NT deletion, we tested the immediate effect of NT removal by protease
cleavage. H1299 cells were transiently transfected with p53c1 and NT truncation mutants (Fig.12A).
The purified p53c1 was cleaved with PreScission protease to remove the NT before incubating with
biotinylated oligonucleotide containing p53-binding site. In this assay, NT cleavage stimulated DNA
binding (Fig.12B). The DNA binding activity of 90-393 was ~4-fold higher than 1-393 in a titration
analysis (Fig.12F). P53c1 with deletion of 1-47 had modestly stronger DNA binding than 1-393 and
was less significantly stimulated by cleavage of remaining residues 48-90. P53c1 with ∆1-82, ∆1-90
deletions and non-cleavable p53 were not stimulated by cleavage (Fig.12B, 12C, 12F). The results
show that the NT inhibits DNA binding by the DBD.
A previous study showed that antibodies against p53 NT epitopes can stimulate DNA binding
in EMSA197. In the oligonucleotide pull-down assay, Pab1801 (epitope: 46-55) and DO-1 (epitope: 1125) also stimulated p53c1 DNA binding (Fig.12C). Pab1801 did not stimulate DNA binding by the ∆147 mutant, suggesting that the antibody acts by neutralizing the inhibitory effect of the NT (Fig.12D).
Pab421 (epitope: 363-372) abrogated DNA binding in the oligonucleotide pull-down assay (Fig.12D),
similar to its effect in DNase footprinting197.
The results above suggest that TAD2/PRR has inhibitory effects on DNA binding. Since the
cleavage assay did not have the sensitivity to further dissect TAD2/PRR region, synthetic peptides
representing TAD2 (48-62) and PRR (75-90) were tested in the DNA binding assay. TAD2 peptide
modestly inhibited DNA binding by 90-393, whereas 2 unrelated control peptides elicited no effect
(Fig.12E). Scrambling the negatively charged TAD2 peptide (SCR48-62) did not abrogate its activity,
suggesting that charge was essential for the peptide activity in this assay (Fig.12E). The PRR peptide
had significant activity that was abrogated by scrambling the sequence, suggesting that it interacts
with the DBD in a sequence-dependent fashion (Fig.12E). In control experiments, both peptides had
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no effect on the DNA binding by full-length p53 (Fig.12G). This was expected since full-length p53 is
already in a self-inhibited state.

Table 1 Binding affinity of the p53 ND fragment (1–312) and DBD (94–312) to the consensus DNA
binding site and scrambled control DNA determined by ITC.

ITC was used to study the effect of the p53 NT on DNA binding by titrating samples of either ND (1-312)
or DBD (94-312) p53 with a 20-bp DNA fragment containing the consensus p53 binding site or a
scrambled binding site. For technical detail, refer to the Methods and Materials section.

Concordant with the results of oligonucleotide pull-down assay, the presence of the NT
decreased the binding affinity of DBD for consensus DNA by 26-fold in ITC experiments (Table 1).
The NT also reduced DBD affinity for nonspecific scrambled DNA by 60-fold. One interesting result
from the ITC experiments is the apparent difference in DNA binding specificity between ND and DBD.
This can be estimated by taking the ratio of Kd values for binding scrambled and consensus DNA. For
the ND, this ratio is 8.2, and for the DBD, it is 3.5. Therefore, the presence of the NT decreases DNA
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binding affinity but increases binding specificity, which is essential for p53 to discriminate the
promoter sites of target genes.

Figure 13 p53 NT inhibits DNA binding in vivo.
(A) Diagram of N-terminal truncated p53 mutants used for inducible expression with lentiviral vectors.
p53 and N-terminal deletion mutants were induced in H1299 cells to comparable levels using doxycycline.
(B) p53 mutant expression was induced by doxycycline for 24 hours. p53 binding to promoters of
conventional p53 target genes, such as p21, MDM2, PUMA and Fas, were determined by ChIP. (C) H1299
(p53 null) and p53 inducible H1299 cells were treated by doxycycline for 24 hours. p53 binding to
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nonspecific repetitive sequences, such as LINE1, Alu1, D5Z1 and D5Z2, were determined by ChIP. (D) p53
binding to nonspecific repetitive sequences, such as LINE1, Alu1, D5Z1 and D5Z2, in U2OS (wt p53), U2OSE6 (p53 null) cell lines were determined by ChIP. (E) 1-393 p53 and 90-393 mutant were induced in
H1299 by doxycycline for 24 hours. p53 binding to nonspecific repetitive sequences, such as LINE1, Alu1,
D5Z1 and D5Z2, were determined by ChIP. (F) 1-393 p53 and 90-393 mutant were induced in H1299 by
doxycycline for 24 hours. p53 binding to specific target promoters (average of p21, MDM2, PUMA, Fas)
and nonspecific repetitive sequences (average of LINE1, Alu1, alpha satellite) were determined by ChIP.
The occupancy by wt p53 was arbitrarily set as 1-fold.

To determine the effect of the NT on DNA binding in vivo, p53 and NT deleted mutants 40393, 70-393, 90-393 were expressed in H1299 cells to similar levels using an inducible lentivirus
vector (Fig.13A). Chromatin IP (ChIP) showed that 70-393 and 90-393 bound to several target gene
promoters (p21, MDM2, PUMA, Fas) with 10-fold and 20-fold higher efficiency respectively than wt
p53 (Fig.13B). DNA binding by 40-393 was similar to full-length p53 (Fig.13B). Therefore, TAD2 and
PRR strongly inhibited specific DNA binding in vivo. To study the occupancy of nonspecific DNA by
p53, we first compared the abundance of repetitive elements LINE1, Alu, and alpha- satellite repeats
by ChIP assay in both H1299 and U2OS cells expressing wt p53 or not. The increased enrichment of
these repetitive sequences demonstrated the binding of p53 to repetitive sequences (Fig.13C, 13D).
Further comparison of p53 with 90-393 mutant showed that the deletion of NT escalated its binding
to repetitive elements by ~20-fold higher on average (Fig.13E). In the same experiments, 90-393
binding to specific targets p21, MDM2, PUMA were on average ~10-fold higher than wt p53 (Fig.13F).
Therefore, removal of the NT stimulated p53 DNA binding but resulted in a ~2-fold loss in specificity
in vivo, which is consistent with our ITC results.
2.4.4 p53 NT promotes dissociation from DNA: evidence from a novel cell-free luciferase
fragment complementation assay
To further investigate how the NT inhibits DNA binding by the DBD, we used an in vitro DNA
binding assay based on luciferase fragment complementation. Previously, luciferase fragment
complementation has been a widely used method to study protein-protein interactions. The reporter
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Figure 14 p53 NT promotes dissociation from DNA.
(A) Diagram of in vitro luciferase fragment complementation assay for detecting p53 dissociation from
DNA. p53-Cluc was incubated with ZF-Nluc and ZPBS oligonucleotide for 30-45 min to assemble active
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complexes. Competitor oligonucleotide containing p53 binding site was added, and luciferase activity was
monitored for an additional 75 min. (B) Diagram of p53-Cluc fusion constructs with or without protease
cleavage site, we also created N-terminal truncated p53c1-Cluc deletions, including 48-393-c1-Cluc, 70393-c1-Cluc, and 90-393-c1-Cluc, for the mapping of the domain that is critical for p53 dissociation from
DNA. (C) p53-Cluc and 90-393-Cluc were pre-incubated with ZF-Nluc and ZPBS oligonucleotide to
assemble active complexes. Competitor oligonucleotide was added (0 min), and luciferase activity was
monitored for 45 min. (D) Cleavable p53c1-Cluc and non-cleavable p53-Cluc were pre-incubated with ZFNluc and ZPBS oligonucleotide in the presence and absence of protease to assemble active complexes.
Competitor oligonucleotide was added (0 min), and luciferase activity was monitored for 45 min. The
luciferase signal of each group at 0 min was arbitrarily set as 1. (E) N-terminal truncated p53c1-Cluc
deletions were incubated with ZF-Nluc and ZPBS oligonucleotide to assemble active complexes.
Competitor oligonucleotide was added at 45 min, and luciferase activity was monitored since the
incubation started. The luciferase signal of each group at 45 min before the addition of competitor
oligonucleotide was arbitrarily set as 1. (F) wt, 46A, 46D, 55A, 55D and 72R p53-Cluc mutations were
incubated with ZF-Nluc and ZPBS oligonucleotide to assemble active complexes. Competitor
oligonucleotide was added at 45 min, and luciferase activity was monitored since the incubation started.
The luciferase signal of each group at 45 min before the addition of competitor oligonucleotide was
arbitrarily set as 1. (G) ZF-Nluc and ZPBS oligonucleotide were pre-incubated for 15 min. p53-Cluc and
90-393-Cluc were added to the reactions with indicated amounts of poly(dI-dC) competitor. Luciferase
activity was determined after 60 min. (H) ZF-Nluc and ZPBS oligonucleotide were pre-incubated for 15
min. Equal amounts of p53-Cluc and 90-393-Cluc were added, and luciferase activity was determined at
indicated time points. (I) Normalization of (H) with luciferase signals at 60 min arbitrarily set as 1.

protein, luciferase, in this case, is split and fused to a pair of interacting partners. If the partners
interact, the luciferase fragments in proximity produce bioluminescence. We adapted the traditional
luciferase fragment complementation assay for rapid determination of DNA binding by p53 in vitro.
The N-terminal domain of luciferase was fused to a high-affinity zinc finger protein (ZF-Nluc), and
the C-terminal domain of luciferase was fused to p53 (p53-Cluc). Incubation of ZF-Nluc and p53-Cluc
with an oligonucleotide containing both the zinc finger and p53 binding sites will place Nluc and Cluc
in close proximity to restore luciferase activity (Fig.14A). Because of the high binding affinity of zine
finger protein to its cognate sequences, the luciferase signal is primarily dependent on the binding of
p53 to its binding site. After the luciferase activity reaches a sufficient level, adding excess oligo
containing only the p53 binding site causes a loss of luciferase activity, presumably by sequestering
p53-Cluc that dissociates from the dual-site oligo (Fig.14A). This simplified system is also applied for
the screening of p53 inhibiting and mutant p53 activating compounds in our laboratory.
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Analysis using this assay showed that deleting the NT (90-393-Cluc, Fig.14B) significantly
reduced p53 dissociation from DNA (Fig.14C). When the p53c1-Cluc construct was used (Fig.14B),
protease cleavage of the NT (producing 93-393-Cluc) reduced dissociation from DNA (Fig.14D),
whereas the protease had no effect on non-cleavable p53-Cluc (Fig.14D). The analysis revealed the
role of NT in promoting p53 dissociation from DNA. Further tests with N-terminal truncated p53c1Cluc deletions, including 48-393c1, 70-393c1, and 90-393c1-Cluc suggested that TAD2 region is an
essential mediator of p53 dissociation from DNA (Fig.14E). However, the phosphormimic mutations
of phosphorylation sites (46A, 46D, 55A, and 55D) and P72R polymorphism do not affect the
association of p53 with DNA (Fig.14F), which might be attributed to insufficient sensitivity of the
assay or the lack of assistance from p53 binding partners in vitro. When equal amounts of p53-Cluc
and 90-393-Cluc (Fig.14B) were tested in the complementation assay, 90-393-Cluc reproducibly
generated approximately 2-fold stronger luciferase activity than p53-Cluc with comparable DNA
binding kinetics after normalization (Fig.14H, 14I), corroborating the stronger DNA binding by 90393 observed in the oligonucleotide pull-down assay (Fig.12B). Despite having stronger DNA binding,
90-393-Cluc was more sensitive to competition by poly(dI-dC) (Fig.14G), which suggested a lower
DNA binding specificity.
2.4.5 NMR reveals a dynamic interaction between the p53 NT and DBD
The structure and dynamics of the ND fragment (1-312) were examined by NMR. Figure 15A
shows an overlay of the 1H-15N heteronuclear single quantum coherence (HSQC) spectra for the apoand DNA-bound ND. The ND fragment binds the consensus site to form a >100 kDa tetramer; thus,
resonances for DBD residues are not visible. However, resonances for the disordered TAD1/2 and
PRR residues are strong because they remain dynamic (Fig.15B)209. In the spectrum of DNA-bound
ND, several of the resonances for residues in TAD1, TAD2, and PRR undergo chemical shift and
intensity changes (Fig15B, 15C).
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Figure 15 Intramolecular interaction between TAD2 and DBD.
(A) Overlay of 1H-15N HSQC spectra for apo (blue) and DNA-bound (red) ND. (B) Expanded view showing
most of the disordered TAD1/2 resonances. (C) TAD2 and PRR residues with the largest chemical shift
changes. (D) Plot of the average amide 1H and 15N chemical shift changes for TAD1/2 and PRR residues in
apo vs DNA-bound ND. The grey line marks the digital resolution of HSQC experiment. (E) Intensity ratios
for TAD1/2 and PRR residues calculated as DNA-bound divided by apo ND. The grey line shows the
expected intensity ratio if there is no interaction. (F) The transverse relaxation rates (R2) of TAD1/2 and
PRR residues in the ND (blue) and the NT (1-89, black).

A plot of the averaged amide 1H and 15N chemical shift changes between apo- and DNA-bound
ND shows the largest differences localize to TAD2 (residues 40-60, also an RPA70 binding site), with
a maximum shift observed for the consistently overlapped resonances of residues W53 and F54
(Fig.15D). Resonances for the PRR also show significant chemical shifts upon DNA binding, consistent
with previously published data where the PRR affects DNA binding174,226.
When comparing the intensity differences of the TAD1/2 region of the apo ND vs the DNAbound ND, we observed an increase in the peak intensities of the residues located in TAD2 resulting
in a maxima for the bound/apo intensity ratio that also overlaps with the RPA70 binding site,
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suggesting that the TAD2 is no longer tumbling with the DBD. Transverse relaxation rates (R2s) were
measured for the apo ND to assess whether residues from TAD1/2 are tumbling more slowly than
expected for an intrinsically disordered protein. This could indicate the presence of direct interaction
between TAD1/2 and the DBD. The R2 values for apo ND and the disordered NT fragment (1-89) are
compared, R2 values for residues in the RPA70 and MDM2 binding sites in ND are elevated when
compared with the rest of the NT residues, consistent with a direct interaction between these regions
and the DBD (Fig.15F).
2.4.6 TAD2 interacts with the DNA binding site on DBD

Figure 16 TAD1/2 induces chemical shifts in DBD.
(A) Overlay of 1H-15N HSQC spectra for apo DBD (green) and ND (blue). (B) Plot of the average amide 1H
and 15N chemical shift changes for apo DBD and ND residues. Residues that contact DNA are indicated
with red triangles, and red arrows show the position of hotspot mutations. (C) Residues with the largest
chemical shifts mapped onto the DBD tetramer (grey) bound to DNA (transparent cyan) (PDB ID: 4hje).
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To locate the interaction site for TAD2 and PRR on the DBD, we compared the 1H-15N HSQC
spectra for the apo ND (1-312) and DBD (94-312) to identify chemical shift differences for residues
in the DBD region of ND (Fig.16A). The largest chemical shifts occur for residues K120, H168, H193,
N210, S240, and a large cluster from R282 to E294 (Fig.16B). DBD residues with the largest chemical
shifts either make contact with DNA or are adjacent to contacting residues (red triangles in Fig 16B).
In addition, some residues with large shifts have been reported to interact with a portion of the NT,
specifically H168/M169 form a pocket where the side chain of W91 binds and presumably stabilizes
protein-protein interactions in the oligomeric form of p53242. Mapping residues with the largest
chemical shifts to the DNA-bound structure of DBD identifies a region localized to the periphery of
the DNA binding cleft (Fig.16C). Overall, the NMR analyses suggest that TAD2 and PRR regions
interact with the DNA binding surface of DBD to block binding to DNA.

2.5 Discussion
The p53 protein and key regulators MDM2 and MDMX contain extensive regions of
disordered sequences that have important functions. In MDM2 and MDMX the disordered central
acidic regions form intramolecular contacts with the RING domain and p53-binding domain to
activate E3 ligase function or inhibit p53 binding142,169,243. The C-terminal tail of p53 interacts with
the DBD of another p53 in the tetramer to stabilize oligomerization and DNA binding190. In this report,
we used several approaches to demonstrate that p53 NT engages in intramolecular or intersubunit
interaction with the DBD to regulate DNA binding. Our results provided mechanistic insight on how
p53 NT deletion and binding of NT antibodies stimulate DNA binding. Furthermore, our in vitro and
in vivo evidence showed the NT differentially regulates specific and non-specific DNA binding,
suggesting a mechanism by which NT-interacting proteins regulate p53 DNA binding specificity in a
physiological setting.
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NMR analysis using the monomeric ND fragment showed that NT-DBD intramolecular
interaction is permissible. However, the interaction is strengthened in p53 dimer or tetramer,
suggesting that intersubunit interaction is favored in the tetramer. The NT-DBD binding causes small
chemical shift changes and negligible secondary structure change in TAD2, suggesting a weak
interaction244. We propose that the NT may regulate DBD DNA binding by nucleic acid mimicry or
electrostatic screening. TAD2 can assume an α helical structure and mimic single-stranded DNA
when bound to RPA70206. The enhanced NT-DBD interaction in p53 oligomers may also favor a
mimicry mechanism. Alternatively, acidic residues in NT may dynamically interact with basic
residues around the DNA binding surface to provide electrostatic screening. Without forming a stable
structure, TAD2 may use multiple weak interactions with the DBD to cause large effect on DNA
binding affinity, as suggested in the polyvalency model245,246. Hydrophobic interactions may also play
a role since W53 and F54 of TAD2 have the largest chemical shift changes despite remaining dynamic
when they interact with DBD. Interestingly, two DBD residues with the largest chemical shift changes
due to the TAD2 interaction are cancer mutation hotspots important for conformation (G245) or DNA
contact (R248).
Krois et al. recently described an interaction between p53 TAD2 and the DBD using NMRlabeled 1-61 spliced to unlabeled 62-393201. Our NMR analysis identified weaker but similar
interactions as reported in the Krois study. The stronger interactions observed in the Krois study is
likely due to their use of full-length p53 tetramers. Our analysis using uniformly labelled 1-312
fragment enabled us to detect additional interactions between the PRR and DBD, and more clearly
determine the effect of NT on DNA binding specificity without interference from nonspecific DNA
binding by the C-terminal tail. Taken together, our work and the study by Krois et al. conclusively
demonstrate the p53 NT is a regulator of DNA binding affinity and specificity in vitro and in vivo,
leading to the intriguing possibility that NT phosphorylation or protein binding may alter NT-DBD
interaction and DNA binding.
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Our in vitro and in vivo analyses provided corroborating evidence that the presence of the NT
reduced DBD DNA binding affinity by ~10-fold but increased sequence specificity by 2-fold. These
NT activities may be biologically relevant in ensuring p53 can rapidly bind and activate target
promoters in stress response. The nuclear level of p53 after stress-induced accumulation is on the
order of 104 molecules per cell247. To specifically search and activate target genes in a timely fashion
during the stress response, p53 may employ scanning and inter-strand transfer mechanism. The p53
CT is involved in nonspecific DNA binding, and sliding that is critical for rapid search of target sites178.
The DBD cannot slide on DNA; its high affinity for nonspecific DNA may interfere with inter-strand
transfer and CT-mediated sliding. By promoting DBD dissociation from DNA, the NT may facilitate
rapid identification of target promoters. Given the large excess of nonspecific DNA sequences in the
genome, the increase in specificity provided by the NT may play important roles in reducing trapping
of p53 by irrelevant sequences.
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CHAPTER 3 REGULATION AND SIGNIFICANCE OF NT-DBD INTERACTION IN P53
3.1 Abstract
In chapter 2, we defined an intramolecular NT-DBD interaction in p53, which modulates DNA
binding. Further investigations showed p53 NT binding proteins, including p53 binding domains
from MDMX, modulate the interaction and thereby regulate p53 binding to specific target sequences.
Full-length MDMX also affects NT-DBD interaction but decreases p53 DNA binding specificity. We
also observed a more robust NT-DBD interaction in mutant p53 than wt p53. Interestingly,
conformational mutants manifest stronger NT-DBD interactions than DNA contact mutants, which
correlates with an enhanced inhibition of mutant p53 association with repetitive sequences.
Furthermore, T55 phosphormimic mutations alter NT-DBD interaction in p53, which is verified by
direct T55 phosphorylation, leading to the hypothesis that T55 phosphorylation might affect p53
functions. We generated a T55 phospho-specific antibody of p53 to investigate the regulation of this
site. The results demonstrate that DNA damaging compounds can promote T55 phosphorylation.
Notably, we observed a correlation of T55 phosphorylation with K382 acetylation in p53. T55A
mutant p53 induces lower mRNA expression level of several important apoptosis-related genes and
higher MDM2 level than wt p53. Consistently, H1299 cells with T55A mutant p53 show significantly
higher cell viability and stronger clonogenic ability than wt p53 containing H1299 cells, suggesting
the importance of T55 phosphorylation in p53 growth suppression activities. Overall, our results
suggest that T55 phosphorylation may regulate NT-DBD interaction, p53 C-terminal modification,
and p53 transcriptional function.
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3.2 Introduction
p53 is a transcription factor that plays a central role in the regulation of cell cycle, apoptosis
and senescence. In unstressed cells, p53 level is kept low under the strict control of its negative
regulators, such as MDM2 and MDMX. The essential role of p53 as a tumor suppressor relies on its
ability to bind to specific promoter DNA and to initiate the transcription of its target genes. Upon DNA
damage or oncogenic stress, p53 is activated via various post-translational modifications, including
phosphorylation of S15, S20 and S46 and acetylation of K382248. The activation of p53 leads to cell
cycle arrest, apoptosis, senescence and metabolic alterations and the existence of p53-MDM2
negative feedback loop ensures p53 activity remains controllable219. MDMX is another critical
negative regulator of p53. Although it fails to degrade p53 with an inactive E3 ligase domain, MDMX
inhibits p53 DNA binding directly or forms heterodimers with MDM2 to assist poly-ubiquitination of
p53122,123. Thus, multiple p53 regulators cooperate to fine-tune p53 activities.
p53 mutation occurs in over 50% of tumors, and the loss of p53 functions by mutation allows
cancer cells to undergo malignant transformation. Nonetheless, numerous studies have revealed GOF
of mutant p53 promotes cancer development or metastasis by interacting with other transcriptional
factors or interfering with other signalling pathways36,67,70. Given advances in crystallization and
computational biology, we are now aware that p53 mutations are distinct and behave differently in
tumorigenesis216. Pharmaceutical rescuing and degradation of mutant p53 have provided proof-ofconcept for targeted cancer therapies72,89. However, the selection force that drives p53 mutation is
still a subject of debate. A recent study with integrative evidence from p53 DNA-binding,
transcriptional sequencing, mouse model and clinical samples, suggested the dominant-negative
effect, but not GOF, is the primary outcome of p53 missense mutations in myeloid malignancies249.
The authors also indicated the GOF of mutant p53 might exist in a context-dependent fashion. Thus,
future studies are required to elucidate the cause and consequence of p53 mutations.
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Results in the previous chapter demonstrated the NT interacts with DBD of p53 and regulates
p53 DNA binding specificity. In this chapter, we continue to investigate the role of NT-DBD
interaction in the contexts of p53 post-transcriptional modifications, binding partner interactions
and p53 mutations. We observed a stronger NT-DBD interaction in mutant p53. The binding of MDMX
to p53 NT modulates NT-DBD interaction and p53 DNA binding activities. Additionally, T55
phosphorylation is critical for NT-DBD interaction, which contributes to p53 target gene expression
and growth suppression activities. These findings provide new insights into how the modulation of
NT-DBD interaction by p53 binding partners and post-translational modifications regulates p53
functions.

3.3 Methods and Materials
3.3.1 Cell lines
Mutant p53 inducible H1299 cells were made by transducing mutant p53-expressing
lentivirus vector into H1299 cells. The individual mutations were introduced by site mutagenesis of
the wt p53-containing vector and confirmed by DNA sequencing. The protocol for lentivirus
production and site mutagenesis were described in chapter 2. H1299, H1299 with inducible p53, and
U2OS with inducible MDMX were cultured in Dulbecco’s modified Eagle medium (DMEM) with 10%
(vol/vol) fetal calf serum at 37˚C in a 95% air, 5% CO2 humidified incubator.
3.3.2 RNA extraction and Real-Time PCR
RNA was isolated from cell culture using the TRIZOL according to the protocol provided by
the manufacturer (Thermo Fisher Scientific). RNA (500ng) was reverse transcribed to cDNA using
TaqMan reverse-transcriptase (Applied Biosystems). SYBR Green Real-Time PCR Master Mixes kit
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(Life Technologies) was used for the thermocycling reaction in an Eppendorf Mastercycler 6300
System. All samples were run in triplicate and were normalized to human actin.
Primer sets:
p21:
(Forward: 5’-CAGACCAGCATGACAGATTTC-3’, Reverse: 5’-TTAGGGCTTCCTCTTGGAGA-3’).
MDM2:
(Forward: 5’-CCCTTAATGCCATTGAACCT-3’, Reverse: 5’-CATACTGGGCAGGGCTTATT-3’).
PUMA:
(Forward: 5’-TGTGAATCCTGTGCTCTGCC-3’, Reverse: 5’-TTCCGGTATCTACAGCAGCG-3’).
Fas:
(Forward: 5’-CACACTCACCAGCAACACCAA-3’, Reverse: 5’-GCTTTCTGCATGTTTTCTGTACTTCC-3’).
actin:
(Forward: 5’-GCTCGTCGTCGACAACGGCTC-3’, Reverse: 5’-CAAACATGATCTGGGTCATCTTCTC-3’).
3.3.3 MTS assay
MTS assay was used to study cell proliferation. 3 × 104 p53 inducible H1299 cells were plated
in 24-well plates and treated with doxycycline for p53 induction and compounds at indicated
concentrations. Cells were incubated at 37°C for 48-72 hours in a humidified, 5% CO2 atmosphere.
Medium was removed, and 0.25 ml fresh medium containing 10 µl MTS reagent (CellTiter 96
AQueous One Solution Reagent from Promega) was added into each well. Another 0.25 ml extra
solution was kept as a blank control. After being incubated for 15-30 min in 37°C incubator, 0.2 ml
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supernatant was transferred into 96-well plates for the measurement of absorbance at 490 nm. All
experiments were performed in triplicate.
3.3.4 Colony formation assay
Colony formation assay was applied to evaluate cellular clonogenic potential. Cells were
digested and resuspended into single cell status. A total of 1,000 cells from each group were cultured
in a 6-well plate for two weeks. After rinsing with PBS, cells were fixed with 50% methanol containing
0.5% crystal violet for staining. Cells were washed with water carefully until excess dye was removed.
The colonies were counted by light microscopy in each well. All experiments were performed in
triplicate.
3.3.5 Drugs and treatments
Doxycycline was applied for doxycycline-inducible gene expression at 20-50 ng/ml for 24
hours. MDM2 inhibitor Nutlin was used at 5–10 μM for 18 hours. The topoisomerase inhibitor
Camptothecin (CPT) was used at 0.5-1 μM for 18 hours. Fluorouracil (5-FU) was used at 50 μM for
18 hours. Cells were exposed to 5-10 Gy irradiation for p53 activation. Compound concentrations
used in experiments were denoted in figures and figure legends.

3.4 Results
3.4.1 MDMX regulates p53 DNA binding specificity
Several important p53 regulators bind to TAD1 or TAD2, including MDM2/MDMX (TAD1),
p300/CBP (TAD1 and TAD2) and RPA70 (TAD2). The effect of MDMX was examined since its p53
binding was empirically more robust than p300 or RPA. In the in vitro DNA dissociation assay, GSTMDMX-1-121 (p53 binding domain) modestly inhibited dissociation of p53-Cluc from DNA (Fig.17A).
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Figure 17 MDMX regulates p53 domain interaction and DNA binding.
(A) p53-Cluc was pre-incubated with ZF-Nluc and ZPBS oligonucleotide to assemble active complexes in
the presence of GST, GST-RPA-1-121, and GST-MDMX-1-120. Competitor oligonucleotide was added (0
min), and luciferase activity was detected at indicated time points. (B) p53c1 was co-expressed with
MDMX-1-200 and MDMX-1-490 in H1299 cells. p53c1 (and the associated MDMX) was immobilized on
M2 beads, cleaved with protease for 40 min, and analyzed for NT-DBD interaction by WB detection of
released 91-393 fragment. (C) p53 was induced by doxycycline with MDMX-1-200 transfection in p53
inducible H1299 cells. Cells were harvested after 28 hours for ChIP assay to determine p53 binding to
specific promoters. (D) U2OS cells expressing doxycycline-inducible MDMX were induced with
doxycycline for 24 hours and treated with 10 Gy gamma radiation. Expression of p53 pathway markers
was determined by WB. (E) U2OS cells expressing doxycycline-inducible MDMX were treated with
doxycycline for 24 hours and irradiated with 10 Gy gamma radiation. p53 binding to specific promoters
(average of p21, MDM2, Fas, PUMA) and repetitive sequences (average of LINE1, Alu, alpha satellite) were
analyzed by ChIP 4 hours after irradiation. The occupancy by p53 in untreated cells was arbitrarily set as
1-fold.
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Co-expression of MDMX-1-200 or full-length MDMX also inhibited the interaction of p53 NT with
DBD in the fragment release assay (Fig.17B). Therefore, MDMX binding may modulate the specific or
nonspecific DNA binding by p53. Co-expression of MDMX-1-200 increased p53 binding to specific
promoters, consistent with its ability to disrupt p53 NT-DBD interaction (Fig.17C).
ChIP analysis of p53 in a U2OS cell line expressing ectopic MDMX (Fig.17D) showed that
MDMX suppressed specific DNA binding and stimulated nonspecific DNA binding, thus reducing the
specificity of p53 in vivo (Fig.17E). DNA damage (gamma radiation) preferentially enhanced p53
binding to specific sites, thus increasing the specificity of p53. In the presence of MDMX, DNA damage
was less effective in stimulating specific binding (Fig.17E). Therefore, MDMX reduced p53 specificity
by blocking binding to specific sites and increasing binding to nonspecific DNA, consistent with its
role as an important p53 inhibitor without promoting degradation.
3.4.2 Significance of ND-DBD interaction in mutant p53
Hotspot p53 mutations can be generally divided into DNA contact and conformational
mutants depending on the role of residues in DNA contact or structure maintenance94. To study the
significance of NT-DBD interaction in p53 mutants, we introduced naturally occurring missense
mutations into cleavable p53 constructs. With FRA, we identified stronger NT-DBD interaction in the
mutant than wt p53 (Fig.18A). To exclude the likelihood of insufficient protease cleavage due to
mutant p53 aggregations, we extended the enzyme incubation time from 30 min to 2 hours.
Interestingly, almost 100% of DBD of conformational p53 mutations, such as 175H and 245D,
remained associated the cleaved NT on beads, which suggests a significantly different structure of
conformational mutations when compared with DNA contact mutations or wt p53 (Fig.18A).
Consistently, 175H and 245S mutants displayed higher proportions of mutant conformation than the
248Q and 273H mutants in Pab1620/Pab240 immunoprecipitation assay (Fig.18B)116. In a ChIP
assay, 273H mutant showed higher occupancy on repetitive sequences than the 175H mutant p53,
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which correlates with a weak NT-DBD interaction in 273H mutant (Fig.18C). As expected, p53
mutants showed no binding to p53 cognate sites (Fig.18C). In summary, our results suggest that the
NT-DBD interaction also regulates the non-specific DNA binding function of p53 contact mutants.

Figure 18 NT-DBD intramolecular interactions are altered in mutant p53 and might affect their
functions.
(A) Mutant p53c1 expressed in H1299 was immobilized on FLAG beads and cleaved by PreScission for 2
hours. The beads and supernatant were analyzed for DBD fragment by WB using FL393 antibody. The
level of p53c1 input was confirmed by WB. (B) H1299 cells were transduced with mutant p53 expressing
lentivirus vectors for stable gene expression. Wt p53 was induced in H1299 cells by doxycycline for 24
hours. Cell lysates were immunoprecipitated with wt conformation-specific (Pab1620) and mutant
conformation-specific (Pab240) antibodies. The precipitated p53 was detected by FL393 in WB. Wholecell extracts were analyzed for protein levels. (C) 175H and 273H mutants were stably expressed in H1299
cells by lentivirus vectors. Wt p53 was induced to a similar level as mutant p53 in H1299 by doxycycline
for 24 hours. p53 occupancy at specific sequences was determined by ChIP. The occupancy by wt p53 was
arbitrarily set as 1-fold.
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3.4.3 T55 is critical for NT-DBD interaction of p53

Figure 19 Effects of p53 NT phosphorylation relevant mutagenesis on NT-DBD interaction.
(A) Diagram of representative phosphorylation and polymorphism sites in p53 NT. (B) Wt and 3D mutant
(15D, 18D, 20D) p53c1 expressed in H1299 were immobilized on FLAG beads and cleaved by PreScission
for 30 min. The beads and supernatant were analyzed for DBD fragment release by WB using FL393
antibody. The level of p53 input was confirmed by WB. (C) FLAG-tagged p53c1 mutants were immunopurified from transfected H1299 cells, cleaved with protease, and incubated with beads loaded with
biotinylated oligonucleotide containing p53-binding site. The captured p53 was detected by WB using
FL393. (D) Wt and mutant p53c2 expressed in H1299 were immobilized on FLAG beads and cleaved by
PreScission for 30 min. The beads and supernatant were analyzed for DBD fragment release by WB using
HA antibody. The level of p53 input was confirmed by WB. (E) Wt p53c2 expressed in H1299 cells were
immunoprecipitated by FLAG beads or other antibodies against p53 NT residues with Protein A beads
and cleaved by PreScission for 30 min. The beads and supernatant were analyzed for DBD fragment
release by WB using HA antibody. (F) Wt p53c2 or empty vector expressed in H1299 cells were
immunoprecipitated by FLAG beads and anti-p-p53-T55 antibody with Protein A beads and cleaved by
PreScission for 30 min. The beads and supernatant were analyzed for DBD fragment release by WB using
HA antibody.
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p53 NT contains many residues that can be phosphorylated by different kinases (Fig.19A).
The phosphorylation of 15, 18 and 20 residues in p53 NT occurs after DNA damage and rescues p53
from MDM2, contributing to the activation of p53250,251. The substitution of 15, 18 and 20 residues
with aspartic acids for phosphorylation simulation did not affect p53 NT-DBD interaction or p53 DNA
binding, presumably because TAD1 is not a primary mediator of NT-DBD interaction (Fig.19B, 19C).
In contrast, phosphormimic T55D mutation increased DBD binding to NT, and T55A phosphomutant
decreased it, which suggested a role of T55 in p53 NT-DBD interaction (Fig.19D).
To further study the effects of T55 phosphorylation on NT-DBD interaction, we used a T55
phosphorylation specific antibody to immunoprecipitate p53c2 in FRA. The results revealed
complete binding of the DBD to the NT in T55-phosphorylated p53c2 (Fig.19E, 19F). This observation
is consistent with the NMR 1H-15N HSQC spectra data showing that T55 directly interacts with the
DBD. Mechanistically, T55D mutation and T55 phosphorylation might increase electrostatic
interaction between negatively charged TAD2 and positively charged DBD, leading to an enhanced
NT-DBD binding. Alternatively, T55 phosphorylation might promote the disorder-to-order formation
of α-helix in TAD2, mimicking single-stranded DNA that interacts with the DBD of p53. Interestingly,
the use of a S15 phosphorylation-specific antibody in FRA also showed a modest increase of DBD
binding to the NT (Fig.19E). Therefore, T55 phosphorylation stimulates p53 NT-DBD interaction.
3.4.4 T55 phosphorylation is induced by DNA damaging compounds and correlates with
K382 acetylation
We immunized rabbits with a synthetic peptide of T55 phosphorylated p53 TAD2 for p-p53T55 specific antibody production. To interrogate the regulation of T55 phosphorylation, p53 was
induced in H1299 cells followed by the treatments of multiple p53 activating compounds. The results
showed that CPT and gamma irradiation stimulated T55 phosphorylation (Fig.20A). To confirm the
antibody is detecting T55 phosphorylation faithfully, we introduced a T55A mutation to ablate T55
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Figure 20 Determination of T55 phosphorylation in p53.
(A) Wt p53 was induced in H1299 cells using doxycycline with different treatments as stated. Cell lysates
were collected for immunoprecipitation of p53 with p53 targeting Pab1801 antibody. T55
phosphorylation and total p53 levels were analyzed by WB. (B) Wt and T55A mutant p53 were induced
to comparable levels in H1299 cells using doxycycline. Lentiviral expression vectors were transduced into
H1299 cells for stable expression of 175H and 273H mutant p53. Cell lysates were collected for
immunoprecipitation of p53 with Pab1801 antibody. T55 phosphorylation and total p53 were analyzed
by WB. S15 phosphorylation, S46 phosphorylation, K382 acetylation, p53 and actin input levels were
confirmed by WB. (C) H1299 cells were transiently transfected with p53c1-luc. Cell lysates were collected
for immunoprecipitation of p53c1-luc with different p53 targeting antibodies. p53c1-luc-containing
beads were incubated with Calf intestinal alkaline phosphatase (CIP) at 37°C to catalyze the
dephosphorylation of p53. T55 phosphorylation, S15 phosphorylation and total p53 levels were analyzed
by WB.
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phosphorylation. Treatment of CPT augmented pT55 in wt p53, but not T55A mutant p53.
Simultaneously, CPT treatment increased K382 acetylation in wt p53, suggesting a requirement of
T55 phosphorylation for K382 acetylation (Fig.20B). Of note, T55A mutant displayed moderately
higher S15 and S46 phosphorylation than wt p53 (Fig.20B).
Three monoclonal p53 antibodies used for p53 enrichments showed remarkably different
precipitation of T55 phosphorylated p53. Pab1801 precipitates T55 phosphorylated p53 efficiently,
whereas Pab421 cannot precipitate T55 phosphorylated p53 (Fig.20C). Previous studies have
already shown that Pab421 antibody only binds to non-acetylated p53223. Thus, our observations
indicated a correlation of T55 phosphorylation with p53 CT acetylation. Interestingly, T55
phosphorylation cannot be dephosphorylated by CIP treatment (Fig.20C). It is possible that the
increased NT-DBD binding protects T55 phosphorylation from CIP enzyme. As a control, S15
phosphorylation can be efficiently precipitated with all three p53-binding antibodies and completely
dephosphorylated by CIP treatment (Fig.20C). Therefore, our results showed that T55
phosphorylation could be induced by DNA damaging treatments and correlate with K382 acetylation
of p53.
3.4.5 Effects of T55A mutation on p53 functions
To characterize the functional effects of T55 phosphorylation, we induced the expression of
wt and T55A mutant p53 to similar levels and determined mRNA level of p53 target genes. Compared
to wt p53, T55A mutant resulted in increased MDM2 and Fas expression along with reduced PUMA
and Bax levels (Fig.21A). Consistent changes of PUMA and MDM2 protein levels in T55A mutant were
observed in p53-expressing H1299 cells in the presence of DNA damaging CPT treatment (Fig.21B).
Although T55 phosphorylation has been previously suggested to regulate promoter binding and p53
subcellular location, it remains unclear whether T55 phosphorylation affects cell viability and colony
formation252. According to the results of MTS assay, T55A mutant p53-containing H1299 cells
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showed higher cellular viability than wt p53-expressing H1299 cells (Fig.21C). Concordantly, T55A
mutation led to more colonies in colony formation assay (Fig.21D). In summary, our results
demonstrate that T55 phosphorylation is important for optimal p53 growth-suppressive activity.

Figure 21 T55A mutation alters p53 function.
(A) Wt and T55A mutant p53 were induced with doxycycline in H1299 cells to similar levels for 24 hours.
Cells were collected for mRNA extraction by TRIZOL reagent. Alterations of mRNA level of p53 target
genes by T55A mutation were confirmed by reverse transcription-quantitative polymerase chain reaction.
Data were normalized to human actin and mRNA level of wt p53 group after doxycycline induction was
arbitrarily set as 1 for comparison. “+”: doxycycline induction of p53; “-“: PBS control. (B) Wt and T55A
mutant p53 were induced with doxycycline in H1299 cells to similar levels for 24 hours. Alterations of
protein level of p53 target genes by T55A mutation under CPT treatment were confirmed by WB in H1299
cells. (C) Growth inhibition of wt and T55A mutant p53 with escalated dosing of CPT were determined by
MTS assay in H1299 cells. Wt and T55A mutant p53 were induced with doxycycline at 50 ng/ml. Data
were normalized as percentages of the untreated control, which was set as 100% viability. (D) Effects of
wt and T55A mutant p53 on the clonogenic potential of H1299 cells were investigated with colony
formation assay. Quantified data were presented as the mean ± standard deviation of three assays. *p <
0.05.
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3.5 Discussion
Conformational-flexible IDRs are critical mediators of cellular signalling, protein interaction,
functional control, and subcellular location162. Phosphorylation and binding partners are common
mechanisms for IDR regulation, leading to conformational changes or disorder-to-order transition.
After the identification of NT-DBD intramolecular interaction in p53, we investigated the significance
of T55 phosphorylation and NT binding partners in NT-DBD interaction and p53 growth suppression.
We also showed stronger NT-DBD interactions in mutant p53. In summary, our results provided
evidence that NT-DBD interaction could be a novel mechanism of p53 regulation.
p53 NT post-translational modifications and binding proteins could affect NT-DBD
interactions, impacting p53 functions. Phosphorylation of T55 by the TAF1 coactivator causes p53
dissociation from DNA during the recovery from DNA damage response187. Phosphorylation of T55
increases NT-DBD interaction and might further inhibits p53 DNA binding. Consistently, a recent
study suggested a delayed increase of T55 phosphorylation after DNA damage, leading to p53
genome-wide dissociation from promoters and inactivation of p53-dependent transcription187. We
also observed altered p53 transcriptional activity in the T55A mutant. Whether T55-induced NT-DBD
interaction causes defective tumor suppression in T55A requires further investigation. Our results
also revealed a novel activity of MDMX that stimulates p53 binding to nonspecific chromatin sites
and inhibit specific DNA binding. MDMX engages in complex multi-domain interactions with p53118.
MDMX N-terminal domain binds to p53 TAD1 and stimulates DNA binding; whereas the central acidic
region interacts with p53 DBD in cooperation with CK1α and inhibits DNA binding. Both MDMX-p53
and MDMX-CK1α interactions are inhibited by DNA damage signalling, providing a mechanism to
activate p53 specific DNA binding during stress response171.
It is a well-established paradigm that loss of sequence-specific DNA binding is a major
consequence of p53 mutation. In breast cancer, patients with p53 missense mutations located in DBD
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are associated with a worse prognosis than those outside of DBD, underscoring the importance of
p53 DNA binding ability253. Further studies found mutant p53 preferentially binds to stereo-specific
non-linear DNA without specific sequence motifs254. It suggested the alteration of DNA binding
specificity rather than loss of DNA binding after p53 mutation. However, the mechanism of mutation
p53 DNA binding remained unclear. Many ChIP-seq experiments ignored repetitive sequences
binding of protein since the first step of analysis is to filter data, retaining reads that map to unique
locations in the reference genome (uni-reads), therefore losing the reads that map to multiple
locations, including repetitive sequences255. However, mutant p53 binds to DNA and protein
promiscuously. According to our results, 273H displays a weaker NT-DBD interaction along with a
higher occupancy on repetitive sequences than 175H mutant, suggesting a correlation of NT-DBD
interaction with DNA binding capacities in mutant p53. The strong NT-DBD interaction in 175H
mutation may inhibit mutant p53 interaction with genomic DNA.
Another interesting finding of our study is the relationship of T55 phosphorylation with K382
acetylation. Previous studies of NT phosphorylation focused on S15 and S46 residues since T55 is
not a conserved residue in mouse p53. Pab421 antibody cannot interact with K382-acetylated p53223.
Our results showed non-acetylated p53 captured by Pab421 was devoid of T55 phosphorylation. The
simultaneous increases of T55 phosphorylation and K382 acetylation in wt p53 rather than T55A
upon the treatment of CPT further corroborate the association of T55 phosphorylation with K382
acetylation in p53. Thus, we speculate that T55 phosphorylation is required for K382 acetylation.
Mechanistically, T55 phosphorylation might promote the recruitment of p300 that subsequently
acetylates K382 of p53. Alternatively, T55 phosphorylation enhances NT-DBD binding, which
potentially interferes with CT-DBD interaction and frees p53 CT for modifications.
The crosstalk between p53 NT and CT has been found to activate p53 cooperatively.
Phosphorylation of S15 promotes p53 interaction with CBP/p300, which further acetylates p53 CT
and stimulates specific DNA binding of DBD223. Conversely, DBD DNA binding also stimulates
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acetylation of p53 CT by p300, which is probably mediated by releasing p53 NT for p300
interaction256. Another crosstalk of p53 post-translation modification was observed between S37
phosphorylation and K382 acetylation257. Efficient K382 acetylation of p53 requires S37
phosphorylation. S37 phosphorylation might influence p53 conformation since recognition of the
PAb240 epitope appears to correlate with phosphorylation of S37. Furthermore, p53 CT binds to the
N-terminal domain of MDM2, contributing to the formation of p53-MDM2 complex181. The inhibition
of p53 DNA binding by MDM2 requires the presence of an intact CT. The acetylation of K382 hinders
p53 NT-MDM2 interaction, which implies a crosstalk between NT and CT of p53181. Considering that
CT can bind to DBD of p53 and promote DNA-induced conformational changes within DBD under
certain conditions, further studies are required to determine how NT-CT, NT-DBD and CT-DBD
interactions coordinate to control p53 tumor suppression activities.
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CHAPTER 4 CONCLUSIONS AND FUTURE DIRECTIONS
This study aims to elucidate the role of p53 NT as an intrinsic disorder region. We showed
that TAD2 and PRR inhibit DNA binding by directly interacting with DBD. NMR spectroscopy
confirmed that TAD2 and PRR interact with the DBD at or near the DNA binding surface, possibly
acting as a nucleic acid mimetic to block DNA binding competitively. Further analyses showed that
the NT reduced p53 DNA binding affinity but improved the ability of p53 to distinguish between
specific and nonspecific sequences. MDMX inhibits p53 binding to specific target promoters but
stimulates binding to nonspecific chromatin sites. The alteration of NT-DBD interactions in T55A and
T55D mutants indicates that T55 phosphorylation might affect p53 functions, which is verified by
functionally defective T55A mutation. The results suggest that p53 NT-interacting proteins and posttranslational modifications may regulate p53 DNA binding partly by modulating the NT-DBD
interaction. In summary, our results extend the role of p53 NT, which is previously considered as
only transactivation domains, to an allosteric regulator of p53 DNA binding and function.
Nonetheless, there are some long-standing critical questions concerning the regulatory mechanism
of p53.
It is widely accepted that p53 induces cell cycle arrest under moderate stress and apoptosis
with severe stimuli, but the mechanism behind the choice of p53 function remains unclear. Although
DNA binding of p53 cannot represent gene transcription, the principle of p53 DNA binding provides
hints about how p53 decides cell fate. Even a single base substitution alteration of the consensus p53
binding motif, RRRCWWGYYY (R = A, G; Y = C, T; W = A, T), affects p53 binding affinity significantly,
especially the central WW nucleotides258. Previous studies revealed more robust binding sites on
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promoters of cell cycle arrest genes than apoptotic genes259. Thus, p53 seems to mediate cell cycle
arrest at low level and initiate apoptosis at high level.
However, it is an imperfect and incomplete model with problems. p53 undergoes multiple
post-translational modifications after stress, which alter DNA binding affinity and specificity. For
example, phosphorylation of S46 primarily promotes apoptosis by the induction of p53AIP1 and the
dissociation of p53 from the apoptosis inhibitor iASPP260,261. Concordantly, p53S46A/S46A KI mice
showed reduced p53-dependent apoptosis and cellular senescence262. In addition, K120 acetylation
appears to preferentially promote apoptosis rather than cell cycle arrest via conformation
switching263. Epigenetic modifications of p53 target sequences and associated epigenetic regulators
might also play a role. For instance, BRD7 promotes the transcription of a subset of p53 target genes
by affecting histone acetylation44.
CT of p53 has been shown to be indispensable for p53 linear diffusion. With the positively
charged lysine and arginine residues in CT, p53 is able to diffuse along DNA, searching for its cognate
binding sites efficiently after DNA damage178. p53 with CT deletion showed impaired specific DNA
binding and target gene expression. The CT enables p53 to bind to those sites that are more divergent
from the consensus p53 binding motif, and the modification or deletion of the CT can drastically alter
the sequence binding specificity of p53176. Bulky acetylation of the p53 CT results in stimulation of
both apoptosis and cell cycle arrest, whereas site-specific acetylation of K370, K372 or K373 only
promotes p53-dependent apoptosis through the interaction with p300264.
For the post-translational modification of the residues that do not directly bind to cognate
sequences, they might affect p53 DNA binding via the modulation of p53 conformation. As discussed
above, the CT interacts with DBD and therefore contributes to a p53 tetramer with high cooperativity
in DNA binding176. Recent publications demonstrated how p53 NT affects DNA binding by interacting
with the DBD, providing evidence for p53 allosteric regulation by the NT201,202. Interestingly, our
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results also revealed a correlation between T55 phosphorylation and K382 acetylation. Therefore,
the regulation of p53 DNA binding might be more complicated than the p53 dosing principle. The
precise binding of p53 to its target sequences requires the cooperation of the NT, CT and DBD. Stress
signals affect partner associations and post-translation modifications of p53 NT and CT. The altered
CT-DBD and NT-DBD interactions coordinate to regulate the binding strength and specificity of p53
DNA binding.
The names on the long list of p53 target genes are responsible for many cellular activities,
including cell cycle arrest, apoptosis, metabolism and senescence, but the exact mechanism by which
p53 relies on for tumor suppression is not well understood. Genetically engineered mouse models
(GEMMs) are instrumental for the evaluation of any given p53 target gene in p53-mediated tumor
suppression265. For example, p21 and PUMA gene knockouts accelerated tumor development but
failed to recapitulate early-onset tumorigenesis in p53 null mice266. Triple-knockout of p21, PUMA
and Noxa impairs p53-dependent apoptosis and cell cycle arrest but does not predispose GEMM to
spontaneous tumor development as p53 deleted mice267. Thus, classical functions of p53 seem to only
partially contribute to p53-mediated tumor suppression.
p53 activation can be induced by either acute DNA damage or chronic stresses. To distinguish
the role of acute and chronic responses of p53 in tumor suppression, p53 is induced in tamoxifeninducible GEMM for 6 days either concurrently with irradiation or 8 days after irradiation268. The
delayed restoration of p53, rather than p53 induction following DNA damage, appears to protect mice
against tumorigenesis268. The results provided evidence that the acute DNA damage response is
dispensable for p53 mediated tumor suppression. Additionally, p533KR (K117R, K161R, and K162R)
is deprived of cell cycle arrest and apoptosis functions but maintains efficient tumor suppression in
gene knock-in mice269. The authors suggested that several metabolic targets of p533KR are responsible
for residual tumor suppression. The results of p533KR corroborated the notion that novel functions of
p53, rather than acute DNA damage response, are essential for p53-mediated tumor suppression.
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L25 and W26 are crucial for TAD1, and F53 and F54 are crucial for TAD2 of mouse p53270.
Mutation of these 4 hydrophobic amino acids to polar amino acids compromises p53 target gene
transactivation and functions. Importantly, p53-mediated cell cycle arrest and apoptosis require full
p53 transcriptional activities and are severely impaired in p5325, 26 and p5353, 54 mutants. However,
p5325, 26 and p5353, 54 mutants retain robust activity in senescence and tumor suppression in GEMM,
suggesting cell cycle arrest and apoptosis are not necessary for p53-mediated tumor suppression217.
Recently, p5353, 54 was found to be a super tumor suppressor for its novel suppression of Yap pathway
in pancreatic cancer41.
In summary, as a hub of cellular signal transduction, p53 plays a central role in growth control
and tumor suppression. A plethora of p53 target genes and pathways integrate to suppress
tumorigenesis. Our identification of the NT-DBD intramolecular interaction provides novel evidence
for p53 regulatory mechanisms, leading to a better understanding of p53 tumor suppression.
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